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ABSTRACT 
 
Evaluation of Unmarked Deletion Mutants as Improved Brucella  
Vaccine Strains in the Mouse and Goat Models.  (August 2005) 
Melissa Marie Kahl, B.S., University of Connecticut 
Chair of Advisory Committee: Dr. Thomas A. Ficht 
 
 
 
Historical data suggests that prolonged survival of Brucella vaccine organisms in 
the target host enhances immune protection.  Recent research has focused upon the 
development of rough vaccine strains to avoid interference with standard diagnostic 
tests.  Rough organisms are rapidly cleared from the host, however.  In an effort to 
develop improved vaccine strains, we have screened signature tagged mutagenesis banks 
to identify mutants with varying survival characteristics.  We hypothesize that in order 
for a vaccine to be efficacious, it must survive in the host.  In order to test this, we 
constructed marked and unmarked deletion mutants of B. abortus and B. melitensis in 
genes previously demonstrated by transposon mutagenesis to attenuate in vivo and in 
vitro virulence.  Survival and efficacy of these novel deletion mutants were then 
evaluated in the mouse model.  The asp24 mutants, which persist for extended periods in 
vivo, appear superior as a vaccine candidate compared to approved vaccine strains S19 
and Rev1 in the mouse model against either homologous or heterologous challenges.  
Once enhanced protection against infection was demonstrated in the mouse, components 
of immune function that appeared to be most important were identified to correlate the 
immune response with the observed protection.  We demonstrated that the most 
 iv 
persistent mutant, ?asp24, affords the greatest protection in mice against virulent 
challenge.  In order to evaluate safety of the novel vaccine strains as well as protection 
against infection and abortion, we tested selected B. melitensis unmarked deletion 
mutants in a natural host, the goat.  The ?asp24 mutant was shown to be safe in pregnant 
goats while providing significant protection against infection and abortion. 
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INTRODUCTION AND LITERATURE REVIEW 
 
BACKGROUND 
The organism.  Brucella species are small, facultative, Gram negative, 
intracellular coccobacilli.  They are classified phylogenetically within the ?-2 
subdivision of Proteobacteria.  The majority of Brucella species are subdivided into 
various biotypes, or biovars, which are defined depending upon growth characteristics 
such as necessity for the presence of carbon dioxide, growth on dyes, H2S production, 
lysis by phage, and agglutination by monospecific sera (80).  The biotypes most 
commonly utilized in research laboratories are strain 2308 (S2308) which is a B. abortus 
biovar 1, 16M which is a B. melitensis biovar 1, and strain 1330, which is a B. suis 
biovar 1 (59). The genomes of most Brucella typically consist of two circular 
chromosomes of approximately 2.1 and 1.5 Mb, without plasmids, distinct from many 
other bacterial species.  One species of Brucella that differs from this scheme is B. suis 
biovar 3, which has only one chromosome, sized at 3.3 Mb.  B. suis biovars 1, 2, and 4 
are sized slightly smaller.  Overall, chromosome I encodes the majority of genes 
involved in transcription, translation, and protein synthesis.  Chromosome II contains 
many genes involved in membrane transport, energy metabolism, and regulation (40, 
59). 
_________________ 
This dissertation will follow the style of the journal, Infection and Immunity. 
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Animal brucellosis.  Most species of Brucella are the etiologic agents of 
brucellosis, a disease that affecting numerous animal species that is also a zoonotic 
disease for humans (6, 23, 27, 40, 53).  There are seven different species of Brucella 
classified primarily by their preferential or normal host.  B. melitensis infects goats, 
sheep, cows, camels, dogs and humans, B. abortus infects cattle, elk, bison, coyotes, 
swine, and humans, B. suis swine, reindeer, dogs, and humans, B. ovis sheep, B. canis 
dogs, B. neotomae the desert wood rat, and the seventh is unnamed but infects marine 
mammals (21, 40, 79, 80).  Exposure in animals most commonly occurs through 
inhalation, or ingestion of infected fetal or contaminated tissues, or in some cases may 
be sexually transmitted (40).  Acute infections in some target ruminant hosts are 
observed after some species of Brucella invade the chorionic trophoblast cells of the 
placenta, resulting in abortion of the fetus.  Persistence is then classified by the 
organism’s ability to reside in reproductive tissues and the mammary gland and lymph 
nodes, chronically shedding into the milk (28).  In animals, brucellosis may cause 
economic losses due to the abortions and infertility (36, 56). 
 
Human brucellosis.  Humans may become infected, commonly by B. abortus, 
B. melitensis, and B. suis, after contact with infected animals, inhalation of aerosolized 
organism, or ingestion of contaminated animal products including meat, milk products 
and milk (7, 56, 69).  In humans, B. melitensis, B. abortus, and B. suis infections cause a 
reoccurring, or undulant, fever, arthritis, osteomyelitis, spondylitis, dementia, and rarely 
meningitis or endocarditis (21, 32, 36).  Human to human transmission is very rare, 
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though it has been reported from tissue transplantation or sexual contact (32).  Even with 
proper antibiotic treatment for humans, chronic infections with recurrent periods of 
disease may occur.  The actual incidence of brucellosis in humans is unknown due to 
poor surveillance and documentation of the disease, but is estimated to be between <0.01 
to >200 per 100,000 people in highly endemic areas (32).  Areas with high prevalence of 
brucellosis include the Middle East, southwest Asia, South and Central America, South-
Eastern Europe, Africa, the Caribbean and the Mediterranean Basin countries (32, 36).   
Due to the highly infectious nature of the organism from aerosol and oral modes 
of transmission, where only a few organisms would be sufficient to cause infection, 
Brucella are considered a biowarfare agent.  Model systems for biological attacks with 
aerosol Brucella estimate a cost of $477.7 million per 100,000 people exposed to the 
attack, with 413 deaths and 82,500 cases of clinical disease (32).  The events of 9/11 
broadened the scope of Brucella research and interest to include the demand for better 
protection and reaction of this country against potential bioterrorist threats.  There is no 
effective or approved Brucella vaccine for use in humans (7, 32, 40, 56). 
 
Transmission.  The normal portal for entry for Brucella in animals occurs 
through nasal, oral, and pharyngeal cavities, where the bacteria penetrate the mucosal 
epithelium.  Depending upon the particular Brucella species, the primary route of 
exposure is varied.  B. abortus and B. melitensis predominately infect the oropharnyx, 
whereas B. suis, B. canis, and B. ovis naturally transmit through the genital tract in 
animals (1).  They are transported in the host to regional lymph nodes in phagocytic cells 
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or alone.  The bacteria then spread and multiply inside macrophages in lymph nodes, 
spleen, liver, bone marrow, mammary glands, and reproductive organs (40). 
 
Pathogenesis.  Brucella species have the ability to resist killing by professional 
phagocytes, such as neutrophils and macrophages, and are allowed to multiply in the 
same cells for maintenance of chronic infections (40, 66).  It is hypothesized that 
Brucella are able to replicate intracellularly by induction of virulence genes, resulting in 
persistence of the organism in the host and subsequent disease (41).  
There are two documented ways Brucella manipulate this intracellular niche.  
The first is accomplished through a recently identified virulence factor, the Type IV 
secretion system, encoded by the virB operon.  It has been demonstrated that Brucella 
evade macrophage killing through VirB-dependent sustained interactions with the 
endoplasmic reticulum, preventing fusion of Brucella-containing vacuoles with 
lysosomes, which is necessary for intracellular survival and multiplication.  Brucella 
virB mutants exhibit reduced survival in vitro and in mice, due to the inability of the 
organism to prevent this fusion and subsequently replicate (8, 10, 11, 14, 41). 
O antigen is also involved in the avoidance of the endosome pathway that 
normally kills pathogens.  It has been shown that smooth strains of B. suis contained 
within phagosomes do not fuse with lysosomes, whereas rough versions fuse rapidly (41, 
63).  Rough mutants have also been shown to be taken up by macrophages in greater 
numbers than smooth organisms and become cytopathic for the macrophages, potentially 
recruiting immune factors and/or aiding the spread of organism to neighboring cells (60).  
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The defined role of O antigen in Brucella pathogenesis is unclear, but it does hold an 
important role in virulence of the organism. 
 
Current prophylaxis.  Overall, prevention and control of the disease in target 
animal species relies mainly upon detection of infected animals and their elimination 
from herds.  Vaccination is used to provide some level of immunity for protection 
against infection and reduction of transmission by reducing abortions (36).  Vaccination 
with live vaccines has proven much more successful than vaccination with heat-killed 
organisms or subunits (42, 49, 54, 55, 69, 78, 81).  In the majority of the United States, 
B. abortus infection in cattle has been successfully eradicated by the combined use of 
vaccination, testing for infection, and slaughter of seropositive animals.  Commonly, 
strain 19 (S19) and more recently, rough Brucella strain 51 (RB51), have been used for 
vaccination in cattle herds.  S19 has several disadvantages, including inducing humoral 
responses that interfere with standard diagnostic tests, leading to confusion 
distinguishing reactor animals that were vaccinated from naturally infected ones.  S19 
protects only 65 to 75 percent of vaccinated cattle, can cause abortions if given to 
pregnant animals, and it is pathogenic to humans as well (36, 58, 76).  RB51 was created 
as an improved vaccine strain that would not interfere with currently available diagnostic 
tests, since it lacks O antigen.  It was derived by repeated passage of 2308 on solid 
media containing various concentrations of rifampin and penicillin, and is less virulent 
than S19 in mice (36, 68, 76).  Accidental exposure of humans to RB51 through needle 
sticks or eye splashes can result in local adverse events, and it is possible that systemic 
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brucellosis could develop (4).  Rev. 1 vaccine was created to prevent B. melitensis 
infections in goats and sheep.  It is resistant to streptomycin, induces positive serology, 
and though attenuated is still virulent in pregnant animals and humans (69).   
 
Disease prevention in target wildlife species. The vaccine strains S19 and 
RB51 vaccines are not ideal for all ruminant species.  In particular, S19 may cause 
abortion when administered to pregnant bison and elk and RB51 fails to protect most 
bison and elk from challenge infection (17, 22).  RB51 vaccination in caribou and 
reindeer is not safe and can cause abortions from the vaccination itself (17).  As a result, 
improved vaccines need to be created that will combine safety and efficacy to target 
species, including livestock and relevant wildlife.  The optimal vaccine candidate should 
be unable to colonize the reproductive tissues in the pregnant ruminant, yet would persist 
long enough to stimulate a protective immune response for protection against abortion 
and infection.  This is particularly important in large free-ranging herds of bison and elk, 
where determining the pregnancy status of animals is virtually impossible.  In bison and 
elk, outbreaks of brucellosis are devastating to the state and domestic herds of 
surrounding states.  States may lose Brucella-free status if the disease is detected in 
domestic herds.  After the loss of Brucella-free status cattle, bison, elk and deer are not 
easily transported from these states, which is a huge economic loss for the livestock 
industry.  There is a demand for safe Brucella vaccines with significant levels of 
protection for both animals and in humans. 
 
 7
CREATION OF DELETION MUTANTS IN B. abortus AND B. melitensis 
 
INTRODUCTION 
The drawback of using transposon mutants as vaccine strains in their present 
state is the very element that allowed identification in the first place: the kanamycin 
resistance.  Since it is not desirable to release an antibiotic resistant Brucella strain into 
the field, particularly one possessing the ability of a movable element (transposon), 
removal of this resistance while retaining attenuation of the mutant is ideal.  There are 
several methods commonly employed to successfully create unmarked gene deletions in 
various bacterial species.  Targeting specific genes by removing them, leaving behind no 
antibiotic resistance, has several advantages over insertion of a transposon or antibiotic 
resistance gene.  Insertional mutagenesis risks the accidental creation of polar effects, 
particularly when the element is inserted within an operon.  It is also possible to 
unintentionally create secondary mutations elsewhere in the chromosome, rather than 
only in the gene of interest (46).  By utilizing homologous recombination between the 
bacterial chromosome and a plasmid carrying cloned chromosomal sequences and a 
selectable marker, unmarked, in-frame deletions can be created.  Mutants generated in 
this fashion were used to demonstrate a correlate between persistence of the mutant and 
efficacy as a vaccine. 
Numerous attenuated mutants have been constructed in Brucella species via 
transposon mutagenesis (2, 27, 38).  The signature tagged mini Tn5 has proven to be 
extremely efficient for identifying several Brucella genes encoding factors or products 
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vital for survival and virulence within the host simultaneously in a single mouse (38, 
44).  Mutants defective for genes required early in infection were rapidly cleared from 
the mouse model and from macrophages in culture.  Mutants defective for genes 
required later in infection were retained longer in the mouse model, and depending on 
the defect may or may not show any difference in the relatively short time span of the 
macrophage assay (<72 hours) (dissertation by Priscilla Hong).  Since mice infected via 
intraperitoneal injection with wild-type B. abortus may retain bacteria within the spleen 
for up to 24 weeks post-infection, the degree of persistence can therefore be compared to 
wild-type infection (38).  Mutants may be assigned to tentative groups based upon their 
rate of clearance from the mouse.  Mutants that clear within two weeks of infection are 
considered highly attenuated, and are designated as class I or II mutants depending on 
whether they recover to normal levels (class II) or do not recover (class I) later.  Class II 
mutants are of little use as vaccine strains.  Class III mutants demonstrate reduced 
survival only after 8 weeks of infection, such as S19 in the mouse (74). 
In order to evaluate protection as a function of persistence of the vaccine strain 
mutants representing two of the different classes described above were selected for 
further study.  Rough mutants were selected as one representative of class I mutants due 
to a lack of interference with current diagnostic tests from an interrupted O-antigen 
portion of the lipopolysaccharide (LPS).  Organisms with intact LPS are considered 
smooth, whereas organisms with interruptions or deletions in LPS components are 
referred to as rough.  Lipopolysaccharide consists of three domains: lipid A, the core 
oligosaccharide, and O antigen (48, 63, 77).  The perosamine O-side chain is an 
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immunodominant antigen, evoking the majority of the antibody response of animals and 
humans infected or vaccinated with smooth Brucella species (68).  O-antigen is the best 
studied virulence factor in Brucella, yet the basis for the attenuated phenotype of rough 
mutants remains contentious (2, 30, 48, 63, 77).  Reliance on O-antigen for serological 
diagnosis of brucellosis is based on potent antibody responses directed against this cell 
surface antigen and interest in the use of rough organisms as vaccines stems from the 
ease of detection of anti-O-antigen antibodies (48, 69).  However, the rapid clearance of 
rough organisms is often considered a weakness of rough vaccine strains preventing a 
long-term protective immune response (48).  Furthermore, the immunity induced by 
RB51 appears to vary from host to host, and is ineffective in several wildlife species (17, 
22). 
The gene chosen for a rough vaccine candidate was manBA.  
Phosphomannomutase, encoded by manB, is an enzyme that converts mannose-6-
phosphate to mannose-1-phosphate, which is necessary for perosamine synthesis and in 
turn O-antigen.  In the mouse model as well as in tissue culture, mutants of this locus 
exhibit reduced survival, and were chosen to evaluate efficacy as a vaccine strain (2, 30, 
48, 63, 77).   
Because of the controversy surrounding the use of rough vaccines we chose to 
also evaluate a second organism from the first class of mutants (group I).  Mutants 
defective in the virB operon were also unable to establish persistent infections past two 
weeks in the mouse STM screen.  This region is homologous to the virB operon in 
Agrobacterium tumefaciens in which it encodes a Type IV secretion system.  This 
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system is described as a family of proteins forming a complex serving to secrete or 
export macromolecules (8, 10).  Various mutants in this operon are avirulent in the 
mouse model, suggesting that a completely functional VirB system is necessary for the 
establishment and maintenance of infection (10, 18), and reduced survival in cultured 
macrophages (8-11, 18, 41). 
In conjunction with Dr. Renée Tsolis’s lab, marked and unmarked deletion 
mutants of virB2 were made.  In A. tumefaciens, this gene encodes a bacterial cell 
surface pilus necessary for protein export (8, 30).  It is hypothesized that without the 
formation of the pilus, factors or proteins that may be secreted by the VirB system of 
Brucella, which have yet to be identified, do not reach their destination, thus reducing 
virulence of the strain.  It was a logical step to construct a knockout of this gene, since 
the pilus is thought to be directly responsible for the transport of effector molecules that 
may be involved in the virulence of Brucella. 
Another mutant identified by Tn5 mutagenesis that would fall into the Class I 
mutants is cydB of the cydDCBA operon of B. abortus.  In E. coli, the genes cydA and 
cydB encode the two subunits of the membrane-bound alternate terminal oxidase for 
microaerobic respiration, cytochrome bd, which may enhance survival at low oxygen 
concentrations or by limiting production of oxygen radicals (15, 23).  Without 
cytochrome bd oxidase in E. coli, oxygen levels can increase in the cytoplasm to 
detrimental quantities.  The Tn5 mutant demonstrated a reduction in survival in the 
mouse model due to the loss of oxidase activity.  This locus was chosen due to its rapid 
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attenuation in vivo, and because it contains both known virulence determinants, the virB 
system and LPS.  
Mutants that are not rapidly cleared in the mouse model have exhibited superior 
protective immunity (Hong, et al, unpublished).  It was desirable to choose a class III 
mutant to compare survival with vaccine efficacy.  The asp24 gene was selected, as 
mutants defective in the 24 kDa acid shock protein persist for extended periods without 
causing the typical chronic infection.  Originally, this protein was identified by its 
increased expression within macrophages, and under low pH conditions in vitro (45).  
Adaptation to low pH occurs for Brucella within the first few hours of growth during a 
period in which intracellular numbers of bacteria declines to 1-10% of bacterial uptake 
(62).  It is hypothesized that a protein such as Asp24 is therefore important for 
replication and dissemination of B. abortus in the host cells during later stages (45).  In 
the mouse (G. Song, data not published), asp24::kan mutants exhibit approximately one 
and a half logs reduction in survival by 8 weeks infection and no reduction was detected 
in macrophages in vitro.  Mutants of this gene will be used to correlate survival with 
protection. 
 
MATERIALS AND METHODS 
Bacterial strains and plasmids for cloning.  E. coli cultures were grown on 
Luria-Bertani (LB, Difco Laboratories) plates overnight at 37°C with or without 
supplementation of kanamycin (100 mg/l), carbenicillin (100 mg/l) or chloramphenicol 
(50 mg/l).  Frozen stocks were prepared in LB broth supplemented with 50% glycerol 
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(v/v) and stored at –80°C.  E. coli cultures used included: DH5? F- ?80dlacZ?M15 
?(lacZYA-argF) U169 recA1 endA1 hsdR17(rk
-, mk
+) phoA supE44 ?- thi-1 gyrA96 
relA1(Invitrogen), Top10 (F- mcrA ?(mrr-hsdRMS-mcrBC) ?80lacZ?M15 ?lacX74 
recA1 ara?139 ?(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG) (Invitrogen), 
DH10B(F- mcrA ?(mrr-hsdRMS-mcrBC) ?80lacZ?M15 ?lacX74 recA1 endA1 
ara?139 ?(ara-leu)7697 galU galK rpsL (StrR) nupG) (Invitrogen). 
Various plasmids were utilized for cloning and electroporation purposes:  
pBluescriptKSII+ from Stratagene (f1+ origin, ApR, ?-galactosidase ?-fragment, pUC 
origin, lac promoter), pKD4 (FLP/FRT, KmR) (37), pCR2.1 from Invitrogen (TA 
overhang for cloning, ApR, KanR), pEX18Ap (sacB, ApR ) (70), and pBBR1.mcs (CmR). 
 
Recombinant plasmid construction.  In order to construct a vector to eliminate 
a gene of interest, primers were designed to amplify sequences flanking the gene to be 
deleted.  These flanking regions are called the 5’ and the 3’ fragment, and were joined to 
one another using overlap extension PCR using specially designed PCR primers.  
Importantly, the reverse primer of the 5’ fragment and the forward primer of the 3’ 
fragment include sequence complimentary to the opposite fragment and a unique 
restriction site.  The 5’ and 3’ fragments were amplified in separate reactions, removed 
from a gel and then purified.  The two products were then used as template for PCR (52).  
The ends of the joined product were trimmed by digestion with the restriction enzymes 
engineered into the primers and the final fragment was gel purified for cloning into 
pBluescript KSII+.  The vector was digested with the same restriction enzyme on the 5’ 
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and 3’ ends of the overlap fragment, and subsequently dephosphorylated to prevent re-
ligation of the vector.  The gel purified overlapping PCR product was then ligated to 
pBluescript. 
The plasmid created by inserting an antibiotic resistance cassette between the 
upstream and downstream fragments of this backbone vector was used to generate 
marked deletion mutants.  A kanamycin cassette was amplified via PCR from the 
plasmid pKD4 with primers containing the unique restriction site located within the 
overlap of the backbone vector, and inserted.  pKD4 is a plasmid created for the FLP-
FRT system whose Kan cassette is the nptII version from Tn5 (16). 
The construction of the plasmid for creation of unmarked deletion mutants 
entailed cloning of the original overlapping PCR product (without the kanamycin 
cassette) into a plasmid containing sacB, which is pEX18Ap (37).  The novel construct 
was removed and inserted into pEX18Ap using the appropriate restriction enzymes.  
This construct is referred to as the unmarked plasmid. 
 
Transformation and selection of recombinant plasmids.  Following ligations 
of the PCR product to the vector, potential clones were transformed into DH5?, DH10B, 
or Top10 competent cells.  40μl of cells were mixed with a 1μl portion of the ligation 
mixture and kept on ice for 30 minutes.  Samples were then heat shocked at 42°C for 30 
seconds, then immediately placed on ice for 2 minutes.  SOC (6% trypticase soy broth 
(w/v), 10mM NaCl, 2.5mM KCl, 10mM MgCl2 and 20mM glucose was added to the 
samples, which were then incubated at 37°C with agitation for one hour.  After the 
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incubation period, portions of the culture were plated onto solid media supplemented 
with appropriate antibiotics and incubated overnight.  Colonies were picked and grown 
overnight in 5 ml cultures with appropriate antibiotics.  Recombinant plasmids were 
purified (Sigma Mini Prep kit) and analyzed using restriction enzymes. 
 
Bacterial strains for electroporation.  Virulent B. abortus strain S2308 was 
obtained from Billy Deyoe at the National Animal Disease Center in Ames, Iowa, from 
an aborted calf passaged once in culture, and frozen as glycerol stocks at –80°C.  B. 
melitensis biovar 1 (16M) was originally acquired from Dr. Philip Elzer at Louisiana 
State University in Baton Rouge, Louisiana, from an aborted goat fetus.  After usage of 
this strain in the 2002 goat safety trial, another virulent isolate was obtained from a 
Texas A&M aborted goat fetus.  This strain was cultured, kept as frozen stocks, and used 
as the parental strain used to generate deletion mutants, as well as the virulent challenge 
strains for controls and in efficacy studies.  To prepare cells for electroporation, 16M 
and S2308 were grown from the frozen stocks on tryptic soy agar (TSA; Difco 
Laboratories) or Brucella agar (Difco Laboratories) to confluence for 3 days at 37°C.  
Bacteria were harvested by carefully scraping bacteria off the plate with a metal spreader 
into 6 ml of PBS (137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM KH2PO4, pH 
7.3).  Bacterial suspensions were removed from the plate using a pipette and transferred 
into a 50ml conical tube.  Typically, two plates of each species were prepared and 
harvested.  The final suspension of 10 ml contains approximately 4x1011 CFU/ml as 
estimated turbidometrically using a Klett meter.  Alternatively, isolated colonies were 
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selected following 72 hours of growth and used to inoculate 5 ml of fresh tryptic soy 
broth (TSB; Difco Laboratories).  These cultures were grown for 48 hours to achieve 
saturation.  Fifty μl of the saturated culture was used to inoculate 50 ml of fresh TSB, 
and cultures are incubated overnight with vigorous shaking at 37°C for 16 (early log) to 
24 (late log) hours, depending upon the growth phase desired.  Liquid cultures grown 24 
hours contained approximately 4x109 CFU/ml. 
 
Creation of marked mutants in B. abortus and B. melitensis.  Marked deletion 
mutants were created in Brucella though electroporation of the marked plasmid into 
either 16M or S2308.  Depending upon whether cultures are grown in liquid or on plates, 
2x1010 to 4x1011 CFU of bacteria, respectively, were pelleted via centrifugation.  The 
supernatant was removed and the cell pellet washed three times with ice-cold water.  All 
centrifugation steps were performed at 1700 x g and 4°C for 15 minutes.  After the final 
wash, the supernatant was decanted, leaving approximately 1 ml in the bottom of the 
conical to resuspend the cells.  Seventy μl of these cell suspensions were used per 
electroporation with varying amounts of plasmid (1-5 μl total, approximating 1 μg 
DNA) in a pre-chilled 1mm gap cuvette (BioRad).  The cells were shocked in a BTX 
electroporation apparatus set at 2.2-2.5kV and 246?.  One ml of SOC-B [6% trypticase 
soy broth (w/v), 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4, and 20mM 
glucose] medium was immediately added to cuvette, and the suspension was transferred 
to a fresh tube (43).  The tubes were left at room temperature for 10 minutes, then 
incubated overnight at 37°C with agitation to prevent settling in the tube.  
 16
Approximately 12-18 hours later, 100 μl portions of the cultures were plated onto TSA 
containing kanamycin @100 μg/ml.  When colonies arose, they were then replica-plated 
onto TSA containing kanamycin @100 μg/ml and carbenicillin @100μg/ml.  Marked 
deletion mutants were kanamycin resistant (KmR) and carbenicillin sensitive (CbS).  
Verification of mutant genotype was obtained via PCR and Southern blot analysis, to 
ensure that the gene of interest was deleted and the kanamycin cassette is retained. 
 
Creation of unmarked mutants in B. abortus and B. melitensis.  The 
unmarked plasmid, containing the sacB gene, insert, and bla gene (same function as 
carbenicillin) was used for electroporation into marked deletion strains.  Utilizing the 
newly created marked strain enhanced selection, since loss of kanamycin resistance 
identified unmarked mutants formed via allelic exchange.  Electroporation conditions 
were identical to those described in the construction of marked mutants.  After 
electroporation, cells were plated onto TSA containing carbenicillin @100μg/ml instead 
of kanamycin to select for the first homologous recombination, i.e. a co-integration.  As 
colonies appeared on the surface of these plates, they were replica-plated onto (a) 
sucrose plates (TSA without salt, containing 6% (w/v) sucrose, without antibiotic), and 
(b) TSA containing carbenicillin @100μg/ml.  Colonies that grew on carbenicillin (CbR) 
but not sucrose (sucroseS) were co-integrates with functional sacB gene, which was 
imperative for counter-selection to create the unmarked mutant.  Resolution of co-
integration occurred spontaneously and was selected for by inoculating 5 ml of sucrose 
broth (TSB, without salt or antibiotics, and supplemented with 6% (w/v) sucrose) and 
 17
incubating for 24 hours with agitation at 37°C.  After 24 hours of growth, the cultures 
did not look saturated because the sucrose was toxic to the majority of the cells, but there 
were enough cells for plating.  Aliquots of 100 μl from undiluted, 10 fold, and 100 fold 
serial dilutions were spread onto sucrose containing media, and incubated at 37°C until 
growth was evident.  Colonies were replica-plated onto (a) sucrose media and (b) TSA 
containing kanamycin @100μg/ml.  Unmarked deletion mutants were sucrose tolerant, 
resulting from the loss of the integrating plasmid containing sacB, and kanamycin 
sensitive, since the original kanamycin cassette was replaced during plasmid integration. 
 
Validation of gene deletions.  Genomic DNA extracts were prepared for 
deletion mutants using the Wizard Genomic DNA Purification Kit (Promega) according 
to the manufacturer’s protocol.  These genomic preps were used as template for PCR, 
using the primers created for the overlapping PCR to detect the deleted region.   
For Southern blots, genomic extracts were digested with restriction enzymes that 
either flank the deleted gene or cut one time within the region.  Samples were 
electrophoresed overnight on a 0.8% (w/v) agarose gel using constant voltage.  The gel 
was soaked in 0.25N HCl for approximately 15 minutes with agitation.  The gel was 
rinsed with ddH20, and then placed in 0.4N NaOH for 10 minutes.  DNA was transferred 
to nylon (ny+) membrane overnight in 0.4N NaOH.  The membrane is then 
prehybridized 4-16 hours at 68°C in prehybridization buffer (1.5X SSPE, 0.1% SDS, 
0.1% NaPPi, 0.5% Blotto, 10% PEG, 0.1 mg/ml ssDNA). 
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Probes were prepared by a hot PCR method, incorporating a P32-labeled dATP 
into the PCR product.  PCR was performed normally except for the substitution of this 
radioactive dATP for unlabeled dATP, and the inclusion of unlabeled dTTP, dGTP, and 
dCTP to the reaction.  After PCR, the product was run through G-50 resin to remove 
unincorporated radiation.  The purified product was then counted on a scintillation 
counter to determine the specific activity (cpm/μg DNA); amount of labeled probe was 
adjusted based upon size of membrane, using 100,000 cpm/cm2 of blot.  The probe was 
then heat denatured for 10 minutes at 95°C, then quenched on ice.  Five to ten ml of 
hybridization buffer (same as prehybridization buffer) was added to the probe and the 
blot was hybridized for at least 4 hours to overnight.  Blots were washed 2 times in 2X 
SSPE/0.1% SDS at room temperature for 10 minutes, 2 times in 1X SSPE/0.1% SDS at 
room temperature for 10 minutes, 1 time in 0.1X SSPE/0.1% SDS at room temperature 
for 10 minutes, then 1 time in 0.1X SSPE/0.1% SDS at 50°for 10 minutes.  The blots 
were exposed to either a phosphoimager or x-ray film for the desired period to give the 
best signal before development. 
 
RESULTS 
Construct development for mutant creation.  Primers were designed using 
MacVector™ to create gene knockouts in Brucella species.  The primers are listed in 
Table 1.  The conditions for the various primer pairs are listed in Table 2.  In total, nine 
vectors were constructed by a two-round PCR technique to create marked and unmarked
 19
 
 
 
TABLE 1.  Primer design for mutant construction and validation 
Primer name Sequence (restriction enzyme engineered) Fragment 
TAF101 5’-GGAATTCGGCAAAGCGAGTGGGTGATTAG-3’ (EcoRI) asp24 upstream 
TAF102 5’-CGGGATCCTGAGCAAGTGCGGGAATAGC-3’ (BamHI) asp24 upstream 
TAF103 5’-CGGGATCCTGGGAATGGAGCGGCTTTAG-3’ (BamHI) asp24 downstream  
TAF104 5’-GCTCTAGATTTGAACACTTGGCGATAGCG-3’ (XbaI) asp24 downstream 
TAF105 5’-CGACTGAAGGCTGGACAGAC-3’ 5’of asp24 deletion 
TAF106 5’-CAAACTGGCTGGAGGAAGC-3’ 3’ of asp24 deletion 
TAF300 5’-CGGGATCCCGCACGTCTTGAGCGATTGTGTAGG-3’ (BamHI) Kan cassette 
TAF301 5’-CGGGATCCCGGGACAACAAGCCAGGGATGTAAC-3’ (BamHI)  Kan cassette 
TAF356 5’-CGGGATCCCTGGAGGAAAACAATCTGGG-3’ (BamHI) manBA upstream 
TAF357 5’-AAGACGGCGCGCCCGAACCTGTATCTGCCTG-3’ (AscI) manBA upstream 
TAF358 5’-GTTCGGGCGCGCCGTCTTAACCCAAAACCGCTTCGTA-3’ (AscI) manBA downstream 
TAF359 5’-GCTCTAGAGGGTTTTCTGATCGATCTGGTAGC-3’ (XbaI) manBA downstream 
TAF204 5’-GGCGCGCCACGTCTTGAGCGATTGTGTAGG-3’ (AscI) Kan cassette  
TAF205 5’-GGCGCGCCGGACAACAAGCCAGGGATGTAAC-3’ (AscI) Kan cassette 
TAF160X 5’-GCTCTAGAGCGTGCTCGGCATTCTCATTATCC-3’ (XbaI) cydBA upstream 
TAF297 5’-TACCGGATCCGGAAAGACCCAAAGTCAGAGGC-3’ (BamHI) cydBA upstream 
TAF298 5’-TTCCGGATCCGGTATTTTTCCTGGCTTTTGGG-3’ (BamHI) cydBA downstream 
TAF299 5’-GCTCTAGAGCAAGGCTCACTTTATGCGGAG-3’ (XbaI) cydBA downstream 
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TABLE 2.  PCR conditions for the different sets of primers used to generate knockout 
mutants 
PCR Conditions for Primer Pairs 
Primer 
Pair 
Hot Start Denature Anneal Elongation # cycles Final 
elongation 
101/102 95°C 
5 min 
95°C 
30 sec 
58°C 
30 sec 
72°C 
45 sec 
30 72°C 
10 min 
103/104 95°C 
5 min 
95°C 
30 sec 
58°C 
30 sec 
72°C 
45 sec 
30 72°C 
10 min 
101/104 95°C 
5 min 
95°C 
30 sec 
58°C 
30 sec 
72°C 
45 sec 
30 72°C 
10 min 
105/106 95°C 
5 min 
95°C 
30 sec 
58°C 
30 sec 
72°C 
1.5 min 
30 72°C 
10 min 
160X/297 95°C 
5 min 
95°C 
30 sec 
62°C 
30 sec 
72°C 
45 sec 
30 72°C 
10 min 
289/299 95°C 
5 min 
95°C 
30 sec 
62°C 
30 sec 
72°C 
45 sec 
30 72°C 
10 min 
160X/299 95°C 
5 min 
95°C 
30 sec 
65°C 
30 sec 
72°C 
1.5 min 
30 72°C 
10 min 
356/357 95°C 
5 min 
95°C 
30 sec 
63°C 
30 sec 
72°C 
1 min 
35 72°C 
10 min 
358/359 95°C 
5 min 
95°C 
30 sec 
63°C 
30 sec 
72°C 
45 sec 
35 72°C 
10 min 
356/359 95°C 
5 min 
95°C 
30 sec 
63°C 
30 sec 
72°C 
1.2 min 
35 72°C 
10 min 
300/301 95°C 
5 min 
95°C 
30 sec 
65°C 
30 sec 
72°C 
1.5 min 
30 72°C 
10 min 
204/205 95°C 
5 min 
95°C 
30 sec 
65°C 
30 sec 
72°C 
1.5 min 
30 72°C 
10 min 
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gene deletions into B. abortus and B. melitensis (Fig. 1).  Nomenclature and details for 
engineered plasmids are listed in Table 3. 
 
Constructs to delete manBA.  The constructs pMMK33 and pMMK31 were 
engineered to delete manBA (Fig. 2).  Primers TAF 356 and TAF 357 were used to 
amplify the region 5’ of the asp24 gene.  Primers TAF 358 and TAF 359 were used to 
amplify the area 3’ of the deletion (Tables 1 and 2).  After purification of these products, 
they were used as templates in a second round of PCR with TAF 356 and TAF 359 to 
ligate the products together.  This product was digested with BamHI and XbaI and 
cloned directionally into pBluescript to create pMMK29.  Cloning of the same PCR 
product into pEX18Ap elicited pMMK31.  Insertion of the kanamycin resistance gene 
from pKD4 via amplification with primers TAF204 and TAF205 into the center of the 
overlap product of pMMK29 by the engineered AscI site created pMMK33 (Table 3). 
 
Constructs to delete cydBA.  The constructs pMMK14 and pMMK11 were 
engineered to delete cydBA (Fig.  3).  Primers TAF 160-X and TAF 297 were used to 
amplify the region 5’ of the asp24 gene.  Primers TAF 298 and TAF 299 were used to 
amplify the area 3’ of the deletion (Tables 1 and 2).  After purification of these products, 
they were used as templates in a second round of PCR with TAF 160-X and TAF 299 to 
ligate the products together.  This product was digested with XbaI and cloned non-
directionally into pBluescript to create pMMK14.  Cloning of the same PCR product 
into pEX18Ap elicited pMMK11.  Insertion of the kanamycin resistance gene from 
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FIG. 1.  Overlapping PCR to generate knockout mutant constructs.  The first round of PCR amplifies areas 
5’ and 3’ of the gene to be deleted.  The forward primer of the 5’ product (F1) contains a unique restriction 
site (R.E. 1).  The reverse primer of the 5’ knockout (B1) contains another unique restriction site (R.E. 2), 
as well as an area of homology to the 3’ fragment.  The forward primer of the 3’ product (F2) contains the 
same restriction site as the reverse primer of the 5’ fragment (R.E. 2) as well as an area of homology to the 
5’ fragment.  The reverse primer of the 3’ fragment (B2) contains a unique restriction site (R.E. 3).  The 
second round of PCR utilizes the PCR products from the first round as templates for a reaction involving 
(F1) and (B2) as the primers.  From this PCR, one product is produced, the overlapping PCR product, 
which joins the two products by the areas of overlap and the unique center restriction site (R.E. 2).  The 
overlapping PCR product can be cloned into a plasmid via R.E.1 and R.E. 3, and antibiotic resistance 
markers can be inserted through R.E. 2. 
5’ of knockout 3’ of knockout 
B1 F1 F2 B2 
3’ of knockout 5’ of knockout 
F1 B2 
5’ of knockout 3’ of knockout 
2)  Round 2 of PCR 
3)  Overlapping PCR Product 
1)  Round 1 of PCR 
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E. 
1 
R.
E.
2 
R.
E.
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R.
E.
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1 
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1 
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E.
3 
R.
E.
2 
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E.
2 
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TABLE 3.  Plasmid nomenclature 
Plasmid 
Nomenclature: 
Plasmid Details: Plasmid Purpose: 
pMMKB TAF101/TAF104 cloned into pEX18Ap To make unmarked 
asp24 deletion 
pMMK8 TAF101/TAF104 cloned into 
pBluescript 
Intermediate plasmid 
pMMK16 pMMK8 separated by TAF300/TAF301 
(kanamycin resistance) 
To make marked asp24 
deletion 
pMMK29 TAF356/TAF359 cloned into 
pBluescript 
Intermediate plasmid 
pMMK31 TAF356/TAF359 cloned into pEX18Ap To make unmarked 
manBA deletion 
pMMK33 pMMK29 separated by TAF204/205 
kanamycin resistance gene 
To make marked manBA 
deletion 
pMMK14 TAF 160X/TAF299 cloned into 
pBluescript 
Intermediate plasmid 
pMMK15 pMMK14 separated by TAF 
330/TAF301 kanamycin resistance gene 
To make marked cydBA 
deletion 
pMMK11 TAF 160X/TAF 299 cloned into 
pEX18Ap 
To make unmarked 
cydBA deletion 
pAV2.2 (18) Plasmid to make marked 
virB2 deletion 
pAS1.1 (18) Plasmid to make 
unmarked virB2 deletion 
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FIG.  2.  Creation of plasmids pMMK29, pMMK33, and pMMK31 for manBA deletion 
mutants.  The region 5’ of manBA was amplified using primers TAF 356/ TAF 357 and 
the region 3’ of the gene was amplified using primers TAF 358/TAF 359 as described in 
the text.  The two products were joined together in a second round of PCR using primers 
TAF 356/ TAF 359.  The product was cloned into pBluescript with BamHI and XbaI to 
elicit pMMK29, and into pEX18Ap with BamHI and XbaI to elicit pMMK31.  A 
kanamycin cassette was amplified from pKD4 with TAF204/205 and cloned into 
pMMK29 with AscI, which was engineered at the overlapping region that joined the 5’ 
and 3’ products together, to elicit pMMK33. 
TAF 356 TAF 359 TAF 356 TAF 359 TAF 356 TAF 359 Kan 
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FIG.  3.  Creation of plasmids pMMK14, pMMK15, and pMMK11 for cydBA deletion 
mutants.  The region 5’ of asp24 was amplified using primers TAF 160X/ TAF 161 and 
the region 3’ of the gene was amplified using primers TAF 162/TAF 163 as described in 
the text.  The two products were joined together in a second round of PCR using primers 
TAF 160X/ TAF 163.  The product was cloned into pBluescript with XbaI to elicit 
pMMK14, and into pEX18Ap with XbaI to elicit pMMK11.  A kanamycin cassette was 
amplified from pKD4 with TAF300/301 and cloned into pMMK8 with BamHI, which 
was engineered at the overlapping region that joined the 5’ and 3’ products together, to 
elicit pMMK15. 
TAF 160X TAF 163 TAF 160X TAF 163 TAF 160X TAF 163 Kan 
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pKD4 via amplification with primers TAF 300 and TAF 301 into the center of the 
overlap product of pMMK14 by the engineered BamHI site created pMMK15 (Table 3). 
 
Constructs to delete asp24.  The constructs pMMK16 and pMMKB were 
engineered to delete asp24 (Fig. 4).  Primers TAF 101 and TAF 102 were used to 
amplify the region 5’ of the asp24 gene Primers TAF 103 and TAF 104 were used to 
amplify the area 3’ of the deletion (Tables 1 and 2).  After purification of these products, 
they were used as templates in a second round of PCR with TAF 101 and TAF104 to 
ligate the products together.  This product was digested with EcoRI and XbaI and cloned 
directionally into pBluescript to create pMMK8.  Cloning of the same PCR product into 
pEX18Ap elicited pMMKB.  Insertion of the kanamycin resistance gene from pKD4 via 
amplification with primers TAF300 and TAF301 into the center of the overlap product 
of pMMK8 by the engineered BamHI site created pMMK16 (Table 3). 
 
Construction of ?manBA deletion mutants.  Marked deletions of manBA were 
not created in B. abortus.  Instead, unmarked deletions were created directly by 
electroporation of pMMK31 into 2308.  Mutants were plated directly onto carbenicillin 
to select for co-integration of the plasmid.  These colonies were replica-patched onto 
sucrose, to identify colonies that were carbenicillin resistant but sucrose sensitive.  These 
colonies were then grown in sucrose; colonies that survived were plated onto TSA and 
tested via acriflavin agglutination to identify rough mutants.  The unmarked strain is 
referred to as BA?manBA. 
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FIG.  4.  Construction of plasmids pMMK8, pMMKB, and pMMK16 for asp24 deletion 
mutants.  The region 5’ of asp24 was amplified using primers TAF 101/ TAF 102 and 
the region 3’ of the gene was amplified using primers TAF 103/TAF 104 as described in 
the text.  The two products were joined together in a second round of PCR using primers 
TAF 101/ TAF 104.  The product was cloned into pBluescript with EcoRI and XbaI to 
elicit pMMK8, and into pEX18Ap with EcoRI and XbaI to elicit pMMKB.  A 
kanamycin cassette was amplified from pKD4 with TAF300/301 and cloned into 
pMMK8 with BamHI, which was engineered at the overlapping region that joined the 5’ 
and 3’ products together, to elicit pMMK16. 
TAF 101 TAF 104 TAF 101 TAF 104 TAF 101 TAF 104 Kan 
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Marked deletions of manBA were created in B. melitensis via electroporation of 
pMMK33 into 16M.  Knockouts were selected by resistance to kanamycin and 
sensitivity to carbenicillin.  Marked deletions are referred to as BM?manBA::Kan. 
Unmarked deletions of manBA were created in B. melitensis via electroporation of 
pMMK31 into BM?manBA::Kan.  Mutants chosen for sucrose counter-selection were 
kanamycin resistant, carbenicillin resistant, and sucrose sensitive.  These colonies were 
grown in sucrose; colonies that survived the selection that were kanamycin resistant 
were unmarked deletion mutants.  The unmarked deletion mutants are referred to as 
BM?manBA.  Deletion mutants were verified by PCR (Fig.  5). 
 
Construction of ?virB2 deletion mutants.  Plasmid constructs to engineer 
deletions of virB2 in Brucella species as well as primers to PCR verify the deletions and 
produce a probe for Southern blotting were kindly given by Renee Tsolis’s lab (18). 
Marked deletions of virB2 were created B. abortus via electroporation of 2308 with 
pAV2.2.  Knockouts were selected by growth on kanamycin and lack of growth on 
carbenicillin.  Marked deletions are referred to as BA?virB2::Kan.  Unmarked deletions 
of virB2 were created in B. abortus via electroporation of pAS1.1 into BA?virB2::Kan.  
Mutants chosen for sucrose counter-selection were kanamycin resistant, carbenicillin 
resistant, and sucrose sensitive.  These colonies were grown in sucrose; colonies that 
survived the selection that were kanamycin resistant were unmarked deletion mutants.  
Unmarked deletions were named BA?virB2.  Mutants were verified by PCR (Fig.  6) 
and Southern blot (Fig.  7). 
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FIG.  5.  PCR validation of B. melitensis manBA deletion mutants.  Genomic DNA was 
prepared as described in the text and amplified with TAF 356/TAF 359 for BM?manBA 
(1465 bp), lanes 3-5; 16M (4410), lane 6; BM?manBA::Kan (3065), lane 7.  A negative 
PCR control was run in lane 1, and Hyperladder I molecular weight marker was run in 
lane 2. 
1500 bp 
4000 bp 
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FIG.  6.  PCR of virB2 deletion mutants.  Genomic DNA was prepared as described in 
the text and amplified with VirB1540F/1973R (18) from BA?virB2::Kan (~1000 bp), 
lane 3; BA?virB2 (199 bp), lane 4; 2308 (433 bp), lane 5; BM?virB2::Kan (~1000 bp), 
lane 6; BM?virB2 (199 bp), lane 7; 16M (433 bp), lane 8.  Hyperladder I molecular 
weight marker was run in lane 1, and a negative PCR control in lane 2. 
400 bp 
1000 bp 
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FIG.  7.  Southern blot validation of virB2 deletion mutants digested with EcoRI.  
Genomic DNA was isolated as described in the text and digested with EcoRI from 
BA?virB2::Kan (5.4 kb), lane 1; BA?virB2 (5.4 kb), lane 2; 2308 (9 kb), lane 3; 
BM?virB2::Kan (5.4 kb), lane 4; BM?virB2 (5.4 kb), lane 5; 16M (9 kb), lane 6.  Both 
marked and unmarked deletions are the same size because of the location of the EcoRI 
site; it was engineered during the cloning of the fragment 3’ of the knockout. 
9 kb 
5.4 kb 
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Marked deletions of virB2 were created B. melitensis via electroporation of 16M 
with pAV2.2.  Knockouts were selected by resistance to kanamycin and sensitivity to 
carbenicillin.  Marked deletions are referred to as BM?virB2::Kan.  Unmarked deletions 
of virB2 were created in B. melitensis via electroporation of pAS1.1 into 
BM?virB2::Kan.  Mutants chosen for sucrose counter-selection were kanamycin 
resistant, carbenicillin resistant, and sucrose sensitive.  These colonies were grown in 
sucrose; colonies that survived the selection that were kanamycin resistant were 
unmarked deletion mutants.  Unmarked deletions were named BM?virB2.  Mutants were 
verified by PCR (Fig.  6) and Southern blot (Fig.  7). 
 
Construction of ?cydBA deletion mutants.  Marked deletions of cydBA were 
created B. abortus via electroporation of 2308 with pMMK15.  Knockouts were selected 
by growth on kanamycin and lack of growth on carbenicillin.  Marked deletions are 
referred to as BA?cydBA::Kan.  Unmarked deletions of cydBA were created in B. 
abortus via electroporation of pMMK11 into BA?cydBA::Kan.  Deletions were verified 
by PCR (Fig.  8).  Mutants chosen for sucrose counter-selection were kanamycin 
resistant, carbenicillin resistant, and sucrose sensitive.  These colonies were grown in 
sucrose; colonies that survived the selection that were kanamycin resistant were 
unmarked deletion mutants.  Unmarked deletions are referred to as BA?cydBA.  Marked 
deletions of cydBA were created B. melitensis via electroporation of 16M with 
pMMK15.  Knockouts were selected by growth on kanamycin and lack of growth on
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FIG.  8.  PCR validation of marked B. abortus cydBA deletion mutants.  Genomic DNA 
was prepared as described in the text and amplified with TAF 160-X/TAF 299 for 
BA?cydBA::Kan (3006 bp), lanes 3-4; 2308 (4172 bp), lanes 6-7.  Negative PCR 
controls were run in lanes 1 and 5; Molecular weight marker Hyperladder I was run in 
lane 2. 
 
3000 bp 
1 2 3 4 5 6 7
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carbenicillin.  Marked deletions are referred to as BM?cydBA::Kan.  Unmarked 
deletions of cydBA were created in B. melitensis via electroporation of pMMK11 into 
BM?cydBA::Kan.  Mutants chosen for sucrose counter-selection were kanamycin 
resistant, carbenicillin resistant, and sucrose sensitive.  These colonies were grown in 
sucrose; colonies that survived the selection that were kanamycin resistant were 
unmarked deletion mutants.  Unmarked deletions are referred to as BA?cydBA.  
Deletions were verified by PCR (Fig.  9) and Southern blot (Fig. 10). 
 
Construction of ?asp24 deletion mutants.  Marked deletions of asp24 were 
created B. abortus via electroporation of 2308 with pMMK16.  Knockouts were selected 
by resistance to kanamycin and sensitivity to carbenicillin.  Marked deletions are 
referred to as BA?asp24::Kan.  Unmarked deletions of asp24 were created in B. abortus 
via electroporation of pMMKB into BA?asp24::Kan.  Mutants chosen for sucrose 
counter-selection were kanamycin resistant, carbenicillin resistant, and sucrose sensitive.  
These colonies were grown in sucrose; colonies that survived the selection that were 
kanamycin resistant were unmarked deletion mutants.  Unmarked deletions are referred 
to as BA?asp24.  Deletion mutants were verified by PCR (Fig.  11) and Southern blot 
(Fig.  12).  
Marked deletions of asp24 were created B. melitensis via electroporation of 16M 
with pMMK16.  Knockouts were selected by resistance to kanamycin and sensitivity to 
carbenicillin.  Marked deletions are referred to as BM?asp24::Kan.  Unmarked deletions 
of asp24 were created in B. melitensis via electroporation of pMMKB into 
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FIG.  9.  PCR validation of unmarked B. melitensis cydBA deletion mutants.  Genomic 
DNA was prepared as described in the text and amplified with TAF 160-X/TAF 299 for 
BM?cydBA (1506 bp), lanes 3-5; 16M (4172 bp), lane 6.  A negative PCR control was 
run in lane 1, and molecular weight marker Hyperladder I was run in lane 2.  The 
positive control 16M did not amplify under the conditions used; a longer elongation time 
was necessary to generate the 4172 bp product.  
 
1500 bp 
1 2 3 4 5 6
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FIG.  10.  Southern blot to detect marked B. melitensis cydBA deletion mutants digested 
with SphI.  Genomic DNA was prepared as described in the text and digested with SphI.  
Lanes: 1, co-integrant plasmid pMMK15 into B. abortus (6000 bp); 2, 2308 (6000 bp); 
3, 16M?cydBA::Kan (1961 bp); 4, pMMK15 co-integrant in 16M (6000 bp); 5, 16M 
(6000 bp).   
 
6000 bp 
1961 bp 
 37
 
 
 
 
 
 
FIG.  11.  PCR of asp24 deletion mutants.  Genomic DNA was prepared as described in 
the text and amplified with TAF 105/106 to detect knockout mutants.  DNA was isolated 
from: BA?asp24::Kan (2849 bp), lane 3; BA?asp24 (1249 bp), lane 4; 2308 (1782 bp), 
lane 5; BM?asp24::Kan (2849 bp), lane 6; BM?asp24 (1249 bp), lane 7; 16M (1782 
bp), lane 8.  Hyperladder I molecular weight marker is in lane 1 and a negative PCR 
control is in lane 2. 
2000 bp 
1000 bp 
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FIG.  12. Southern Blot to validate asp24 deletion mutants digested with RsaI.  Genomic 
DNA was prepared as described in the text and digested with RsaI for: BA?asp24::Kan 
(1261 bp), lane 1; BA?asp24 (648 bp), lane 2; 2308 (1178 bp), lane 3; BM?asp24::Kan 
(1261 bp), lane 4; BM?asp24 (648 bp), lane 5; 16M (1178 bp), lane 6.  The deleted 
region (asp24) is 530 bp.  The probe contains one RsaI site, therefore two products are 
detected in the Southern blot.  The size of the marked mutant is greater than wild-type 
organism by the kanamycin cassette (1600 bp).  
1261 bp 
1187 bp 
648 bp 
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BM?asp24::Kan.  Mutants chosen for sucrose counter-selection were kanamycin 
resistant, carbenicillin resistant, and sucrose sensitive.  These colonies were grown in 
sucrose; colonies that survived the selection that were kanamycin resistant were 
unmarked deletion mutants.  The unmarked deletion mutant was named 
BM?asp24.Mutants were verified by PCR (Fig.  11) and Southern blot (Fig.  12). 
 
DISCUSSION 
Genes of interest were chosen based upon different survival characteristics of 
mutants, which was a random approach or to target known virulence factors as a rational 
approach.  Brucella abortus rough mutants exhibit reduced virulence in the host and 
traffic differently than smooth organisms.  They are taken up in greater numbers by 
macrophages than smooth strains of the same species, and resulting from this increased 
uptake, cause cell death of the macrophages (60).  The rough mutants may therefore 
follow a different intracellular pathway than smooth organisms, and should be 
considered as vaccine strains since they are not virulent to the host (60, 64).  Normal 
trafficking of Brucella involves the uptake via receptor molecules, localizing in early 
phagosomes, and avoidance of fusion between this Brucella-containing vacuole (BCV) 
and lysosomes (10, 35). Without this inhibition of fusion, the bacteria would be killed 
following the formation of the phagolysosome.  Brucella then traffics so that it reaches 
the endoplasmic reticulum, where it begins replication following the formation of a 
replicative compartment with ER-like properties.  This intracellular trafficking (late 
maturation events only) is controlled by the Type IV secretion system encoded by the 
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VirB operon.  It has been demonstrated that ?virB mutants are unable to sustain the 
interactions with the ER, and are killed when the BCV fuses with lysosomes (10).  A 
virB deletion was chosen because of its inability to traffic normally and therefore 
exhibits reduced virulence.  Mutants of cydBA were chosen because they represent a 
Class I mutant that retains all the known virulence factors.  Since it clears rapidly from 
the host but still produces factors that may be important for proper immune stimulation, 
it may be a superior vaccine candidate to those currently available.  
The class III mutant, asp24, was chosen as an example of a mutant that persists 
for a longer period in the host, though is an attenuated strain.  Similar to the cydBA 
mutant, it also retains all the known virulence factors that may contribute to protective 
immunity.  The contribution of Asp24 to intracellular trafficking is unknown, but may 
play an important role since the protein is up-regulated in infected macrophages, perhaps 
to establish the intracellular niche and, in turn, chronic infections. 
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EVALUATION OF MUTANT CANDIDATES IN THE MOUSE MODEL 
 
INTRODUCTION 
Although the mouse is not a normal host for Brucella species, they will develop a 
systemic infection after intraperitoneal (i.p.) injection with the bacterium and have been 
frequently utilized as a model due to this reproducible colonization (44, 61). The most 
frequently used strain, BALB/C, have 10 fold higher levels of recoverable bacteria in 
their spleens than C57BL/6 mice during the plateau phase of infection, when the CFU 
per spleen becomes constant.  There are two main explanations regarding resistance of 
C57BL/6 mice to Brucella infection.  First, BALB/C mice experience a decline in IFN? 
production beginning at one week post infection that continues until the end of the 
plateau phase at around 6 weeks post infection.  The origin of this decline is unknown 
(50, 51).  The C57BL/6 mice, on the other hand, do not experience this decrease in IFN?.  
Second, in contrast to BALB/C, C57BL/6 mice are NRAMP-susceptible strains, 
suggesting that control of infection originate from other genetic loci (50, 67).  Overall, 
BALB/C that are infected with S2308 are less able to control infections compared to 
C57BL/6 mice, and as such, the increased susceptibility provides a sensitive model to 
evaluate bacterial survival.  To compare any of the mutant strains, standard clearance 
curves of B. abortus S2308 and B. melitensis 16M were created to begin modeling the 
disease in the susceptible BALB/C mouse strain. 
Competitive infection assays are often used to evaluate competition between the 
wild-type organism and the attenuated mutant in the same animal.  This allows direct 
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comparisons of splenic colonization, and minimizes mouse-to-mouse variation while 
ensuring that the delivery of the dose is standardized.  Signature tagged mutagenesis 
utilizes the same approach as competitive infections, in which more than one mutant 
competes in the same mouse (38).  Novel marked and unmarked mutants will be 
compared in two ways.  First, marked mutants are compared to wild-type, to 
demonstrate the degree of attenuation due to the genetic defect.  Secondly, marked 
mutants are compared to unmarked mutants, to ensure that the two mutants can be used 
interchangeably and to identify any polar effects resulting from insertion of the 
kanamycin cassette. 
In contrast to the competitive infection assay, the non-competitive assay mimics 
utilization of the mutant as vaccine in the field, and emphasize the duration of 
persistence of the vaccine strain under non-competitive conditions.  Evaluation of 
colonization singly is important since the presence of wild-type organism may influence 
clearance of attenuated mutants from the host, and suggest enhanced rates of clearance. 
To evaluate the vaccine potential of the selected unmarked mutants, the level of 
protection afforded against virulent challenge will be assessed as a measure of efficacy.  
This will be accomplished by comparing the mean CFU/spleen between naïve and 
vaccinated mice that are subsequently challenged with wild-type organism at various 
timepoints.  Mutants demonstrating a significant decrease in mean bacterial colonization 
of the spleen relative to the control will be considered viable vaccine candidates for 
further evaluation.  Since the mouse is not a perfect model of brucellosis in target 
species, vaccine candidates from the mouse will need to be re-evaluated in a target 
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animal model to evaluate protection against abortion.  Mice do not abort in response to 
Brucella infections, though they will develop placentitis and fetal pathology (75, 76).  
As such, protection against abortion as a measure of vaccine efficacy for livestock and 
wildlife can not be assessed from the mouse model.  
Immune responses to Brucella infections have been mainly studied in mice.  In 
this model, protective immunity appears to be mediated by both a humoral and cellular 
response.  Studies demonstrated that both CD4+ and CD8+ T lymphocytes are important 
for the control of infection (5, 58, 81).  CD4+ T cells are separated into at least two 
subpopulations based upon the cytokines they secrete when stimulated with antigen, 
either Th1 or Th2.  Th1 cells, which secrete such cytokines as IL-2 and IFN-gamma, are 
involved in macrophage activation and attraction of inflammatory cells.  This type of 
response is usually characterized by strong cell-mediated immunity and low humoral 
response.  Th2 lymphocytes typically produce cytokines such as IL-4, IL-5, IL-6, and 
IL-10.  IL-4 and IL-10 are known to downregulate the Th1 response.  Th2 responses are 
usually associated with high titer antibody responses but poor delayed type 
hypersensitivity reactions (34, 82).  It has been shown that lymphocytes from mice 
infected with live Brucella produce high levels of IFN-gamma and other Th1 cytokines, 
whereas mice immunized with heat killed bacteria or bacterial extracts seem to elicit a 
Th2 type response, and it is assumed that a Th1 type response is necessary to control 
Brucella infections (81, 82).  Vaccine candidates are typically evaluated in mice by their 
induction of Th1 versus Th2 cytokines as an explanation of efficacy. 
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MATERIALS AND METHODS 
Bacterial strains.  Virulent B. abortus strain S2308 was obtained from Billy 
Deyoe at the National Animal Disease Center in Ames, Iowa, from an aborted calf and 
passaged once in culture, and frozen as glycerol stocks at –80°C.  B. melitensis biovar 1 
(16M) was originally acquired from Dr. Philip Elzer at Louisiana State University in 
Baton Rouge, Louisiana, from an aborted goat fetus.  After usage of this strain in the 
2002 goat safety trial, another virulent isolate was obtained from a Texas A&M aborted 
goat fetus.  This strain was cultured, stored as frozen stocks, and used as the parental 
strain to generate deletion mutants, as well as virulent challenge strain in efficacy 
studies.  Strain 19 was obtained from the National Veterinary Services Laboratory in 
Ames, Iowa.  Rev 1 INRA was obtained from Dr. Menachem Banai.  All wild-type, 
vaccine and unmarked deletion strains were routinely grown on tryptic soy agar (TSA; 
Difco Laboratories) or Farrell’s media (TSA supplemented with Oxoid Brucella 
supplement) at 37°C and 5% CO2.  Marked deletion mutants were grown on TSA 
supplemented with 100 μg/ml kanamycin.  Bacteria were grown to confluence on solid 
media for 72 hours and harvested into PBS (Gibco, pH 7.4) for each experiment.  Cell 
density is estimated using a Klett meter and the strains are resuspended to the 
appropriate concentrations for each experiment.  All bacteria are listed in Table 4. 
 
Clearance of wild-type Brucella from BALB/c mice.  Groups of 4-5 mice at 4-
6 weeks of age were infected intraperitoneally with either 1x105 CFU/animal or 1x106 
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TABLE 4.  Brucella vaccine strains and deletion mutants used in the mouse 
model 
B. abortus Strain B. melitensis Strain Relevant Characteristic(s) 
2308 16M Wild-type  
Strain 19 (S19) Rev 1 Accepted vaccine strain 
BA?asp24::kan BM?asp24::kan Marked asp24 deletion 
BA?asp24 BM?asp24 Unmarked asp24 deletion 
BA?virB2::kan BM?virB2::kan Marked virB2 deletion 
BA?virB2 BM?virB2 Unmarked virB2 deletion 
 BM?manBA::kan Marked manBA deletion 
BA?manBA BM?manBA Unmarked manBA deletion 
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CFU/animal and held for a time-course experiment to model the clearance of virulent 
2308 and 16M from mice.  At sequential timepoints post-infection, mice were sacrificed 
by CO2 asphyxiation, spleens collected and weighed, homogenized in 1 ml PBS, serially 
diluted, and plated in duplicate onto solid media. 
 
Competitive infection assays.  For competitive infection assays, 4-6 week old 
female BALB/c mice purchased from Jackson Laboratories were infected via 
intraperitoneal injection with a mixture of bacteria in a 1.5:1 ratio of colony forming 
units at a final concentration of 2.5x105 CFU/ml wild-type and unmarked mutants.  The 
final ratio of input bacteria was determined after mixing the cultures together following  
serial dilution and plating in the presence of appropriate antibiotics.  Treatment groups 
included wild-type B. abortus or B. melitensis with marked mutant or unmarked mutant 
plus marked mutant.  Mice were sacrificed at selected time points post-infection, 
depending upon the anticipated clearance rate of each mutant.  At each time point, five 
mice were euthanized via carbon dioxide asphyxiation.  Spleens were collected, 
homogenized in 1 ml PBS, serially diluted, and plated in duplicate onto both TSA and 
TSA containing kanamycin @100μg/ml. Recovered bacteria were enumerated after 4 
days of incubation.  Bacteria growing on TSA represent both populations of mutants, 
therefore subtraction of the bacteria enumerated on kanamycin from those enumerated 
from TSA demonstrated the number of either wild-type or unmarked mutant.  The 
survival index represents the output ratio (wild-type/mutant) divided by the input ratio. 
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Non-competitive infection assays.  Survival of mutants was evaluated by 
vaccinating groups of 4-6 week old female BALB/c mice via intraperitoneal injection of 
1x106 CFU mutant or wild-type organism.  Mice are vaccinated at a ten-fold higher dose 
in the non-competitive assays since the mutant is attenuated, and as such higher amounts 
or organism are used to ensure proper vaccination and presentation to the host.  
Treatment groups included mice vaccinated with either 16M, 2308, or unmarked 
deletion mutants of 16M or S2308 genetic backgrounds.  Mice were sacrificed via 
carbon dioxide asphyxiation at varying times post-infection, depending upon the 
anticipated clearance rate due to the class of mutant.  Spleens were collected and 
weighed, homogenized in 1 ml PBS, serially diluted, and plated onto TSA.  Recovered 
bacteria were enumerated and compared to the other groups to evaluate the rate of 
persistence of each individual organism. 
 
Efficacy studies.  The mouse model was used to evaluate efficacies of various 
unmarked deletion mutants against infection.  Groups of 6-10 female 4-6 week old 
BALB/c mice are vaccinated via intraperitoneal injection of 1x106 CFU/ml of unmarked 
deletion mutant or PBS in naïve controls.  Mice were subsequently challenged with 
1x104 CFU homologous wild-type strain at 12, 16, or 20 weeks after vaccination.  One 
week after the virulent challenge, the mice were euthanized, spleens extracted and 
weighed, homogenized in 1 ml PBS, serially diluted and plated onto TSA.  Bacterial 
burden in the spleen of challenge organism was used as a measure of protective 
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immunity [log10 wild-type recovered from unvaccinated mice minus log10 wild-type 
recovered from vaccinates].  
 
Cross-Brucella species protection.  Groups of five female 4-6 week old 
BALB/c mice are vaccinated via intraperitoneal injection of 1x106 CFU/ml of unmarked 
deletion mutant or PBS in naïve controls.  Mice were subsequently challenged with 
1x104 CFU heterologous wild-type strain at 16 weeks after vaccination.  One week after 
the virulent challenge, the mice were euthanized, spleens extracted and weighed, 
homogenized in 1 ml PBS, serially diluted and plated onto TSA.  Bacterial burden in the 
spleen of challenge organism was used as a measure of protective immunity [log10 wild-
type recovered from unvaccinated mice minus log10 wild-type recovered from 
vaccinates]. 
 
Statistical analysis.  ANOVAs were performed to compare treatment groups of 
mice to one another.  P values less than 0.05 were considered significant. 
 
Cytokine production.  Mice were allocated to four groups of 5: (a) unvaccinated 
controls (b) unvaccinated for 20 weeks then challenged with wild-type for 1 week (c) 
vaccinated for 21 weeks and euthanized without wild-type challenge (d) vaccinated for 
20 weeks then challenged with wild-type for 1 week.  This was performed for both B. 
melitensis and B. abortus strains, as well as for three of the vaccine candidates.  For the 
memory response from splenocytes, mice were euthanized and spleens collected.  
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Spleens were then pressed through fine mesh into a sterile Petri plate, and then flushed 
with PBS.  Cells were pelleted at 1700 x g for 10 minutes; to the supernatant 10ml ACK 
red blood cell lysis buffer (0.15M NH4Cl, 10.0mM KHCO3, 0.1mM Na2EDTA) was 
added for 5 minutes.  Splenocytes were pelleted and washed three times with PBS and 
then enumerated using a hemacytometer.  Splenocytes were resuspended in RPMI 
complete [RPMI 1640, 10% (v/v) FBS, 1% (v/v) sodium pyruvate, 0.1% (v/v) ?-
mercaptoethanol (v/v), 1% penicillin-streptomycin (v/v),] and seeded at a density of 
2x105 cells/well (73).  Samples were stimulated with 1x108 heat killed Brucella.  
Controls included unstimulated cells for a baseline level, as well as cells stimulated with 
ConA, a positive control mitogen, at a concentration of 2μg/ml in each well.  All 
samples were analyzed in triplicate.  Cells were incubated for three days of growth in the 
presence of the stimulant.  Supernatants were collected for cytokine evaluation at day 
three and then frozen at –80°C.  
 
Cytokine ELISAs.  Enzyme-linked immunosorbent assays (ELISAs) were 
performed to characterize the cytokines produced by the splenocytes in response to the 
various stimulants (Peprotech, New Jersey).  Plates were coated overnight at room 
temperature with 50 μl capture antibody at 1 μg/ml for IFN-gamma, IL-4, Il-10, Il-12, 
and 2μg/ml for IL-2.  Wells were washed four times with 300μl PBS-T (0.05% Tween-
20 in PBS) to remove capture antibody.  The blocking reagent (1% BSA in PBS) was 
added to each well at a volume of 300μl and incubated overnight at 4°C.  Plates were 
washed four times with PBS-T to remove the excess blocking reagent.  Cytokine 
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standards were 2-fold serially diluted to generate a standard curve; the specificity 
differed between cytokines.  Tissue culture supernatants were also added in duplicate to 
wells at a volume of 50μl and incubated at 4°C overnight.  Plates were washed four 
times with PBS-T to remove residual supernatant.  Detection antibody was added to 
wells at a concentration of 0.5μg/ml for IFN-gamma, IL-4, and IL-10, and at 0.25μg/ml 
for IL-2 and IL-12 and incubated for two hours at room temperature.  Plates were 
washed four times with PBS-T to remove the detection antibody.  Avidin peroxidase 
(50μl of a 1:2000 dilution) was then applied to each well, and after incubating for 30 
minutes at room temperature, the plates were washed seven times with PBS-T for 
complete removal of the compound.  ABTS liquid substrate (2,2'-Azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid, Sigma Catalog # A3219) was added to each well 
(100μl, ready-to-use concentration), and the plates were incubated at room temperature 
until the highest standard reached 1.2 O.D. units or the zero standard reached 0.2 O.D. 
units, and the reaction was subsequently stopped with 1% SDS.  Plates were read at 405 
nm with wavelength correction set at 650 nm. 
 
RESULTS 
Clearance of wild-type Brucella from BALB/c mice.  The kinetics of clearance 
of wild-type Brucella was evaluated in mice to establish baseline levels of splenic 
colonization for comparison of mutant survival.  B. abortus displayed chronic 
persistence in BALB/c mice injected with 1x105 CFU i.p. (Fig.  13).  B. abortus 
 51
 
 
 
 
 
 
FIG.  13.  Time-course of clearance of 1x105 CFU B. abortus 2308 from mice.  Mice 
were infected with 2308 at 1x105 CFU/animal I.P. for various durations to monitor the 
clearance of the organism.  Mice were euthanized at the various timepoints post-
infection via CO2 asphyxiation, spleens extracted and weighed, then serially diluted in 1 
ml peptone saline.  Serial dilutions were performed and plated to determine the CFU in 
the spleen at each timepoint.  Degree of splenomegaly from the challenge inoculum was 
determined by the weight of the spleen at each timepoint.  Data was plotted as the 
average CFU recovered per spleen +/- standard error of the mean.
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colonizes and replicates in the spleen rapidly, then evolves into a plateau period where 
the bacteria persist in the spleen without dramatic decreases in numbers.  Survival of the  
organism gradually decreases over a period of several months.  B. melitensis does not 
cause chronic disease in BALB/c mice similar to B. abortus, however B. melitensis 
infection in mice caused a similar trend early in infection as B. abortus (Fig.  14). 
Though it was able to establish a severe acute infection, B. melitensis steadily cleared 
from the host, a phenotype that differs from B. abortus.  Several aspects of infection 
were common to both, however.  The greatest degree of bacterial colonization of the 
spleen was detectable at 1 week post-infection, and the greatest degree of splenomegaly 
was observed at two weeks post-infection for both species.  
 
Competitive infections of manBA deletion mutants.  In order to ensure 
deletion stains were attenuated, marked mutants were compared competitively to wild-
type strains, and unmarked mutants were compared to marked mutant strains of the same 
genetic defect.  Using this experimental model, a discrepancy was observed.  In the 
presence of wild-type organism, BM?manBA::Kan was severely attenuated by 1 week 
post-vaccination, and completely cleared by 2 weeks (Fig. 15).  In contrast, marked and 
unmarked BM?manBA and BA?manBA deletions persisted until 2 weeks post-
vaccination, though they were cleared by 5 weeks, when mice were not co-infected with 
wild-type 16M (Fig. 16).  This suggests an inability of the rough strain to compete for an 
intracellular niche when wild-type organism is present.  As a result, a false rate of 
clearance is observed for the mutant strains, though they are still attenuated.  The use of 
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FIG.  14.  Time-course of clearance of 1x106 CFU B. melitensis 16M from mice.  Mice 
were infected with 16M at 1x106 CFU/animal I.P. for a timecourse study.  Mice were 
euthanized at the various timepoints post-infection via CO2 asphyxiation, spleens 
extracted and weighed, then serially diluted in 1 ml peptone saline.  Serial dilutions were 
performed to determine the CFU in the spleen at each timepoint.  Degree of 
splenomegaly from the challenge inoculum was determined by the weight of the spleen 
at each timepoint.  Data was plotted as the average CFU recovered per spleen +/- 
standard error of the mean.
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FIG.  15.  Competitive clearance of marked BM?manBA::kan deletion mutants from 
mice in the presence of 16M.  Mice were co-infected with 16M and BM?manBA::Kan at 
a ratio of 1.5:1 for several weeks.  At each timepoint, mice were euthanized, spleens 
extracted, and homogenized in 1 ml peptone saline.  Aliquots were plated on TSA and 
TSA/Kan@100 to determine the persistence of the bacteria in the spleen.  Bacteria that 
grew on the plates containing Kan represent the remaining marked mutant strain; 
bacteria growing on TSA represent both 16M and the marked mutant, therefore 
subtraction of the CFU from the Kan plates from the CFU on TSA equals the remaining 
16M.  Data was plated as the average CFU recovered from spleens +/- standard error of 
the mean.  
 55
 
 
 
 
 
FIG.  16.  Competitive clearance of unmarked BM?manBA and marked 
BM?manBA::Kan deletion mutants from mice.  Mice were co-infected with 
BM?manBA and BM?manBA::Kan at a ratio of 1.5:1 for several weeks.  At each 
timepoint, mice were euthanized, spleens extracted, and homogenized in 1 ml peptone 
saline.  Aliquots were plated on TSA and TSA/Kan@100 to determine the persistence of 
the bacteria in the spleen.  Bacteria that grew on the plates containing Kan represent the 
remaining marked mutant strain; bacteria growing on TSA represent both unmarked and 
marked strains, therefore subtraction of the CFU from the Kan plates from the CFU on 
TSA equals the remaining BM?manBA.  Data was plated as the average CFU recovered 
from spleens +/- standard error of the mean.
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these strains as vaccines would display a varied pattern of clearance, when the mutant is 
administered to an animal alone. 
 
Clearance of unmarked manBA deletion mutants.  Infection of mice non-
competitively demonstrates the clearance of the vaccine strain without influence of fully 
virulent wild-type strain, to model field vaccination conditions.  Compared to 2308, the 
unmarked B. abortus manBA deletion mutant (BA?manBA) was significantly attenuated 
by 3.39 logs at 1 week post-infection (p<0.0001), 2.44 logs at 2 weeks post-infection 
(p<0.0001), and undetected by 5 weeks post-infection (p<0.0001) (Fig. 17).  Between 1 
and 2 weeks post-infection, however, the levels of detectable vaccine strain in the 
spleens remained unchanged, indicating the ability of the organism to evade killing by 
the host during this time.  Unmarked B. melitensis deletion mutants of manBA 
(BM?manBA) demonstrated a similar trend as BA?manBA (Fig.  18).  Compared to 
wild-type 16M, the mutant was attenuated 2.53 logs at 1 week (P=0.01), 1.33 logs at 2 
weeks (P=0.001), and undetected by 5 weeks post-infection (P=0.001).  Numbers of 
bacteria in the spleen remained unchanged between 1 and 2 weeks post-infection, as was 
observed in the B. abortus mutant.  From these data, we consider the manBA unmarked 
deletion highly attenuated. 
 
Clearance of unmarked virB2 deletion mutants.  Mice infected with unmarked 
B. abortus virB2 (BA?virB2) deletion mutants were attenuated 1.62 logs at 2 weeks 
post-infection (P=0.003), though the attenuation compared to 2308 is not as severe as
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FIG.  17.  Clearance of 1x106 CFU BA?manBA from mice.  Mice were infected with 
BA?manBA at 1x106 CFU/animal.  At each timepoint, mice were euthanized via CO2 
asphyxiation, spleens collected, the homogenized in 1 ml peptone saline.  The quantities 
of mutant remaining in the spleens were determined by serial dilutions of the spleen 
homogenates, and were represented as CFU per spleen +/- standard error of the mean. 
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FIG.  18.  Clearance of 1x106 CFU BM?manBA from mice.  Mice were infected with 
BM?manBA at 1x106 CFU/animal.  At each timepoint, mice were euthanized via CO2 
asphyxiation, spleens collected, the homogenized in one ml peptone saline.  The 
quantities of mutant remaining in the spleens were determined by serial dilutions of the 
spleen homogenates, and were represented as CFU per spleen +/- standard error of the 
mean. 
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FIG.  19.  Clearance of 1x105 CFU BA?virB2 from mice.  Mice were infected with 
BA?virB2 at 1x105 CFU/animal.  At each timepoint, mice were euthanized via CO2 
asphyxiation, spleens collected, the homogenized in one ml peptone saline.  The 
quantities of mutant remaining in the spleens were determined by serial dilutions of the 
spleen homogenates, and were represented as CFU per spleen +/- standard error of the 
mean. 
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what was demonstrated with the BA?manBA mutant at the same timepoint (Fig.  19).  
BAV2 was attenuated 4.68 logs at 6 weeks post-infection (P<0.0001), which was barely 
greater than the limit of detection.  It was undetected at 10 weeks post-infection 
(P<0.0001). 
Unmarked B. melitensis virB2 (BM?virB2) demonstrated similar survival 
characteristics to the B. abortus form, although the degree of attenuation was slightly 
higher (Fig.  20).  In this case, the mutant was attenuated by 2 weeks as well, however it 
was 2.15 logs reduced compared to 16M (P=0.001).  By 6 weeks post-infection, the 
mutant strain was no longer detected from the mouse spleens (P<0.0001), which held 
constant at 10 weeks as well (P=0.002).  From these data, we consider both BA?virB2 
and BM?virB2 to be attenuated at a moderate rate when compared to wild-type strains 
since they are not cleared as rapidly as manBA deletion mutants. 
 
Clearance of unmarked asp24 deletion mutants.  The two asp24 deletion 
mutants were the first set of gene deletions that portrayed varied survival phenotypes in 
the mouse model depending upon in which species of Brucella the deletion was created.  
For the B. abortus version (BA?asp24), the mutant was highly attenuated (4.6 logs) by 6 
weeks post-infection (P<0.0001), barely detectable and 4.98 logs reduced at 8 weeks 
(p<0.0001) and below the limit of detection at 10 weeks (P<0.0001) (Fig.  21).  In B. 
melitensis, however, BM?asp24 is not reduced in the spleen at a significant level until 
16 weeks post infection, where it persists at 1.22 logs lower than 16M (P=0.04) (Fig.  
22).  One difficulty in assessing the difference between 16M and the knockout arises
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FIG.  20.  Clearance of 1x105 CFU BM?virB2 from mice.  Mice were infected with 
BM?virB2 at 1x105 CFU/animal.  At each timepoint, mice were euthanized via CO2 
asphyxiation, spleens collected, the homogenized in one ml peptone saline.  The 
quantities of mutant remaining in the spleens were determined by serial dilutions of the 
spleen homogenates, and were represented as CFU per spleen +/- standard error of the 
mean. 
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FIG.  21.  Clearance of 1x106 CFU BA?asp24 from mice.  Mice were infected with 
BA?asp24 at 1x106 CFU/animal.  At each timepoint, mice were euthanized via CO2 
asphyxiation, spleens collected, the homogenized in one ml peptone saline.  The 
quantities of mutant remaining in the spleens were determined by serial dilutions of the 
spleen homogenates, and were represented as CFU per spleen +/- standard error of the 
mean..
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FIG.  22.  Clearance of 1x106 CFU BM?asp24 from mice.  Mice were infected with 
BM?asp24 at 1x106 CFU/animal.  At each timepoint, mice were euthanized via CO2 
asphyxiation, spleens collected, the homogenized in one ml peptone saline.  The 
quantities of mutant remaining in the spleens were determined by serial dilutions of the 
spleen homogenates, and were represented as CFU per spleen +/- standard error of the 
mean. 
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from the fact that 16M clears at a rapid rate compared to 2308 in mice.  As such, 
differences between 16M and knockouts are not as apparent for mutants that are 
attenuated yet persistent, such as BM?asp24.  
 
Protection against homologous 2308 challenge infection.  To evaluate the 
vaccine potential of the selected unmarked mutants, the level of protection afforded 
against virulent challenge was assessed.  Degree of efficacy was determined by 
subtracting the mean CFU/spleen recovered from mice after vaccination from the mean 
CFU/spleen recovered from age-matched non-vaccinated but challenged controls.  This 
value is referred to as the U value, for units of protection, and is only relative to the non- 
vaccinated controls challenged with the respective wild-type at each particular time 
point. 
At 13 weeks post-vaccination, mice were protected most significantly against 
2308 challenge at 4.72 U by BA?asp24 (P<0.0001).  S19 vaccinated mice were 
protected at 4.28 U (P<0.0001) (Fig.  23).  Mutants that clear more quickly from the 
host, BA?virB2 and BA?manBA, protected mice to a lesser degree at 1.47 and 0.99 U, 
respectively (P=0.004 and P=0.001).  At 16 weeks post-vaccination, challenge bacteria 
were recovered barely above the limit of detection from only one of the four mice 
vaccinated with BA?asp24 (P<0.0001).  S19 protected mice to a great degree at this 
time point as well, at 4.89 U (P<0.0001).  Mice vaccinated with BA?virB2 exhibited 
only 1.49 U protection (P=0.002) or 1.33 U with BA?manBA (P=0.03).  This suggests 
again that the persistent yet attenuated mutant strains protect mice better than rapidly
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FIG.  23.  Protection afforded to mice by B. abortus unmarked deletion mutants against 
virulent 2308 challenge.  Mice were vaccinated with 1x106 CFU unmarked B. abortus 
deletion mutants for 12, 16, or 20 weeks.  After the vaccination period, the mice were 
challenged with 1x104 CFU wild-type 2308 for 1 week.  Mice were then euthanized, and 
spleens extracted and homogenized in 1 ml peptone saline.  Homogenates were serially 
diluted to determine the remaining CFU bacteria in the spleens.  
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cleared mutants do.  At 21 weeks post-vaccination, BA?asp24 protected mice 4.54 U 
(P<0.0001), S19 at 4.29 U (P=0.0001), BA?virB2 at 1.82 U (P=0.001), and BA?manBA 
at 0.07 U (P=0.86).  Overall, the BA?asp24 mutant protects mice against virulent 2308 
challenge to the greatest degree even compared to another persistent mutant strain (and 
patented vaccine strain), S19.  BA?virB2 and BA?manBA protect mice to a moderate, 
though significant degree at most time points tested, except for BA?manBA after 20 
weeks of vaccination, which elicited no significant protection. 
 
Protection against homologous 16M challenge infection.  Mice were 
vaccinated with B. melitensis unmarked deletion mutants and challenged with 16M to 
determine the protection afforded against subsequent infection due to the vaccine strains. 
At 13 weeks post vaccination, BM?asp24 vaccinated mice were protected most 
significantly from 16M challenge, at 3.74 U (P<0.0001) (Fig.  24).  Rev1 vaccinated 
mice were protected at 2.42 U (P=0.002).  Unlike BA?manBA, whose degree of 
protection was less than BA?virB2, the BM?manBA mutant protected mice better than 
BM?virB2, at 1.87 U compared to 1.53 U, respectively (P=0.04 for both strains).  At 17 
weeks post-vaccination, BM?asp24 mice were protected 5.6 U (P<0.0001), Rev1 at 4.12 
U (P<0.0001), BM?manBA at 3.85 U (P=0.0002), and BM?virB2 at 3.8 U (P=0.0001).  
At 21 weeks post-vaccination, BM?asp24 affords the greatest degree of protection at 
4.69 U (P<0.0001), followed by Rev1 at 4.39 U (P=0.0002).  At this timepoint, the 
BM?manBA mutant protects mice better than BM?virB2, similar to the trend
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FIG.  24.  Protection afforded to mice by B. melitensis unmarked deletion mutants 
against virulent 16M challenge.  Mice were vaccinated with 1x106 CFU unmarked B. 
melitensis deletion mutants for 12, 16, or 20 weeks.  After the vaccination period, the 
mice were challenged with 1x104 CFU wild-type 16M for 1 week.  Mice were then 
euthanized, and spleens extracted and homogenized in 1 ml peptone saline.  
Homogenates were serially diluted to determine the remaining CFU bacteria in the 
spleens. 
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demonstrated at 13 weeks post-vaccination, at 4.14 U versus 2.82 U, respectively 
(P=0.0001 and P<0.0001).  Although all vaccine strains protected mice significantly, the 
BM?asp24 mutant afforded mice the greatest protection against 16M challenge in these 
experiments. 
 
Protection against heterologous challenge: Cross Brucella-species protection.  
Mice were challenged with a heterologous wild-type strain to determine if the vaccine 
would be protective against another species of Brucella.  When challenged with 2308, 
the BM?asp24 mutant afforded the greatest degree of protection, at 4.19 U (P<0.0001) 
(Fig.  25).  For this experiment, BM?virB2 afforded more protection against 2308 
challenge (3.30 U, P<0.0001), and BM?manBA the least at 1.60 U (P=0.02).  Mice that 
were vaccinated with BA?asp24 were protected against challenge with 16M to a very 
high degree, at 5.06 U (P<0.0001) (Fig.  26).  The BA?virB2 mutant, though significant 
as compared to the mock-vaccinated mice at 2.11 U (P=0.0001), did not protect as well 
as BA?asp24.  Mice vaccinated with BA?manBA were protected 2.15 U (P=0.002), 
which is similar to the BA?virB2 mutant.  These data indicate that, similar to the 
homologous efficacy data, an attenuated mutant that persists for a longer period in the 
host and contains all the known virulence factors protects better than mutants without 
these characteristics. 
 
IFN-gamma production from mouse splenocytes.  To evaluate a major 
component of the Th1 response in vaccinated mice, splenocytes were assayed for levels 
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FIG.  25.  Protection afforded to mice by B. melitensis unmarked deletion mutants 
against virulent 2308 challenge.  Mice were vaccinated with 1x106 CFU unmarked B. 
melitensis deletion mutants 16 weeks.  After the vaccination period, the mice were 
challenged with 1x104 CFU wild-type 2308 for 1 week.  Mice were then euthanized, and 
spleens extracted and homogenized in 1 ml peptone saline.  Homogenates were serially 
diluted to determine the remaining CFU bacteria in the spleens.
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FIG.  26.  Protection afforded to mice by B. abortus unmarked deletion mutants against 
virulent 16M challenge.  Mice were vaccinated with 1x106 CFU unmarked B. abortus 
deletion mutants for 16 weeks.  After the vaccination period, the mice were challenged 
with 1x104 CFU wild-type 16M for 1 week.  Mice were then euthanized, and spleens 
extracted and homogenized in 1 ml peptone saline.  Homogenates were serially diluted 
to determine the remaining CFU bacteria in the spleens. 
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of IFN-gamma, which is known to aid the regulation of Brucella infections in these 
animals.  Production of IFN-gamma from splenocytes of vaccinated and 
vaccinated/challenged mice were evaluated by ELISA.  Heat killed Brucella was used as 
the stimulant to compare Brucella-specific proliferation and cytokine production from 
the splenocytes of the mice.  Splenocytes from unvaccinated mice that were either 
challenged with 2308 or 16M did not produce detectable levels of IFN-gamma in vitro 
when compared naïve mice in this study (Fig.  27).  Splenocytes from mice vaccinated 
with BA?asp24 and BM?asp24 produced a significant amount of IFN-gamma 
(P=0.0002 and P=0.006, respectively) in response to heat killed Brucella (Fig.  28).   
After challenge, the two strains exhibited different patterns.  The level of IFN-
gamma dropped significantly in BA?asp24 vaccinates after challenge with 2308 
(P=0.03).  For mice vaccinated with BM?asp24, the level of IFN-gamma did not 
decrease after challenge with 16M and there was no significant change between the two 
groups.  The BM?asp24 vaccinated and challenged group was significantly greater than 
naïve mice for IFN-gamma production (P=0.001).  The virB2 mutants also exhibited an 
interesting change in IFN-gamma levels after challenge, where both BA?virB2 and 
BM?virB2 exhibited down-regulation of IFN-gamma in vitro, though the level was not 
significant due to the variation between mice (Fig.  29).  The rough BM?manBA mutant 
did not produce significant amounts of IFN-gamma as compared to control mice (Fig.  
30).
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FIG.  27.  IFN-gamma production from unvaccinated mice with and without challenge.  
Mice were not vaccinated and allowed to rest for 20 weeks before they were challenged 
with 1x104 16M or 2308.  One group of naïve mice was left unchallenged for a baseline.  
Spleens were extracted and splenocytes were isolated as described in the text.  Cells 
were either unstimulated, stimulated with 1x108 heat killed Brucella, or stimulated with 
ConA.  Supernatants were collected after three days and assayed by ELISA for the 
production of IFN–gamma. 
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FIG.  28.  IFN-gamma production from mice vaccinated with ?asp24 deletion mutants.  
Mice were vaccinated for 20 weeks with 1x106 CFU unmarked asp24 deletion mutants 
before they were challenged with 1x104 16M or 2308.  Spleens were extracted and 
splenocytes were isolated as described in the text.  Cells were either unstimulated, 
stimulated with 1x108 heat killed Brucella, or stimulated with ConA.  Supernatants were 
collected after three days and assayed by ELISA for the production of IFN–gamma.  
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FIG.  29.  IFN-gamma production from mice vaccinated with ?virB2 deletion mutants.  
Mice were vaccinated for 20 weeks with 1x106 CFU unmarked virB2 deletion mutants 
before they were challenged with 1x104 16M or 2308.  Spleens were extracted and 
splenocytes were isolated as described in the text.  Cells were either unstimulated, 
stimulated with 1x108 heat killed Brucella, or stimulated with ConA.  Supernatants were 
collected after three days and assayed by ELISA for the production of IFN–gamma. 
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FIG.  30.  IFN-gamma production from mice vaccinated with BM?manBA.  Mice were 
vaccinated for 20 weeks with 1x106 CFU unmarked BM?manBA before they were 
challenged with 1x104 16M or 2308.  Spleens were extracted and splenocytes were 
isolated as described in the text.  Cells were either unstimulated, stimulated with 1x108 
heat killed Brucella, or stimulated with ConA.  Supernatants were collected after three 
days and assayed by ELISA for the production of IFN–gamma. 
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IL-10 production from mouse splenocytes.  To evaluate a cytokine that 
typically counteracts IFN-gamma with anti-inflammatory properties, levels of IL-10 
were assayed from splenocytes of vaccinated mice.  The overall trend for IL-10 
production was that naïve mice challenged with 2308 or 16M produced the cytokine in 
greater amounts in vitro after challenge (Fig.  31), as was evident for BA?asp24 and 
BM?asp24 mutants after challenge (Fig.  32).  BA?virB2 and BM?virB2, however, 
produced less IL-10 overall after challenge (Fig.  33).  IL-10 production from 
BM?manBA vaccinated mice with and without challenge remained unchanged (Fig.  
34).  Except for the unvaccinated group challenged with 16M (P=0.003), there was no 
significant difference between mice challenged and not challenged for the same vaccine 
strain.  When compared to the naïve controls, however, IL-10 levels from BM?asp24 
vaccinates were significantly increased before challenge (P=0.02) as well as after 
challenge (P=0.005), and BA?asp24 was greater before challenge (P=0.05). 
 
IL-12 production from mouse splenocytes.  Extremely low amounts of IL-12 
were detectable for mice vaccinated with 16M?asp24 before challenge, though not 
significant.  IL-12 was significantly detected only from naïve mice after 16M challenge 
(P=0.009).  There was not any significant production of IL-12 for any of the B. abortus 
groups. 
 
IL-2 production from mouse splenocytes.  IL-2 production was increased for 
mice vaccinated with BM?asp24 both before and after challenge (Fig.  35).  No other
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FIG.  31.  IL-10 production from unvaccinated mice with and without challenge.  Mice 
were unvaccinated and allowed to rest for 20 weeks with before they were challenged 
with 1x104 16M or 2308.  One group of mice was left unchallenged for a baseline.  
Spleens were extracted and splenocytes were isolated as described in the text.  Cells 
were either unstimulated, stimulated with 1x108 heat killed Brucella, or stimulated with 
ConA.  Supernatants were collected after three days and assayed by ELISA for the 
production of IL-10. 
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FIG.  32.  IL-10 production from mice vaccinated with ?asp24 deletion mutants.  Mice 
were vaccinated for 20 weeks with 1x106 CFU unmarked asp24 deletion mutants before 
they were segregated into two groups, either unchallenged or challenged with 1x104 16M 
or 2308.  Spleens were extracted and splenocytes were isolated as described in the text.  
Cells were either unstimulated, stimulated with 1x108 heat killed Brucella, or stimulated 
with ConA.  Supernatants were collected after three days and assayed by ELISA for the 
production of IL-10. 
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FIG.  33.  IL-10 production from mice vaccinated with ?virB2 deletion mutants.  Mice 
were vaccinated for 20 weeks with 1x106 CFU unmarked virB2 deletion mutants before 
they were segregated into two groups, either unchallenged or challenged with 1x104 16M 
or 2308.  Spleens were extracted and splenocytes were isolated as described in the text.  
Cells were either unstimulated, stimulated with 1x108 heat killed Brucella, or stimulated 
with ConA.  Supernatants were collected after three days and assayed by ELISA for the 
production of Il-10. 
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FIG.  34.  IL-10 production in mice vaccinated with BM?manBA.  Mice were vaccinated 
for 20 weeks with 1x106 CFU unmarked BM?manBA before they were segregated into 
two groups, either unchallenged or challenged with 1x104 16M.  Spleens were extracted 
and splenocytes were isolated as described in the text.  Cells were either unstimulated, 
stimulated with 1x108 heat killed Brucella, or stimulated with ConA.  Supernatants were 
collected after three days and assayed by ELISA for the production of IL-10.
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FIG.  35.  IL-2 production from mice vaccinated with B. melitensis deletion mutants.  
Mice were vaccinated for 20 weeks with 1x106 CFU unmarked B. melitensis deletion 
mutants before they were segregated into two groups, either unchallenged or challenged 
with 1x104 16M.  Spleens were extracted and splenocytes were isolated as described in 
the text.  Cells were either unstimulated, stimulated with 1x108 heat killed Brucella, or 
stimulated with ConA.  Supernatants were collected after three days and assayed by 
ELISA for the production of IL-2.
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groups demonstrated an increase in production.  The group vaccinated with BA?virB2 
displayed an elevated average of IL-2 before challenge, but due to the variation between 
mice, this was not significant.  There was no detectable production of IL-2 after 
challenge for the B. abortus group. 
 
IL-4 production from mouse splenocytes.  Overall, there was no significant 
production of IL-4 from splenocytes stimulated in vitro with heat killed Brucella. 
 
DISCUSSION 
Competitive infection assays have been used historically to evaluate competition 
between the wild-type organism and the attenuated mutant in the same animal.  This 
allowed for direct comparisons of splenic colonization, and minimized mouse-to-mouse 
variation while ensuring that the delivery of the dose was standardized.  Signature 
tagged mutagenesis utilizes the same approach competitive infections, in which multiple 
mutants compete with one another in the same mouse (38).  Novel marked and 
unmarked mutants were compared in two ways.  First, marked mutants were compared 
to wild-type, to demonstrate the degree of attenuation due to the genetic defect.  
Secondly, marked mutants are compared to unmarked mutants, to ensure that the two 
mutants can be used interchangeably and to identify any polar effects resulting from 
insertion of the kanamycin cassette.  The downfall of this assay is that the degree of 
attenuation of particular mutants is, in our well documented example, exacerbated by the 
presence of wild-type organism.  Since both types of bacteria were competing for the 
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same intracellular niche, the attenuated organism may have been out-competed by the 
better-equipped wild-type strain.  This was the case for both BA?manBA and 
BM?manBA mutant strains, whose presence was rapidly eliminated from mice in a 
competitive infection scenario with wild-type organism, but not when mice were 
vaccinated with the mutant strains alone.  For assays such as signature tagged 
mutagenesis, this effect is useful for identifying mutants that are attenuated, but it is not 
accurate for identifying survival characteristics. 
In contrast to the competitive infection assay, the non-competitive clearance 
assay evaluated non-competitive growth of attenuated mutants in the mouse.  These 
experiments mimicked utilization of the mutant as vaccine in the field, and emphasized 
the duration of persistence of the vaccine strain under non-competitive conditions.  
Evaluation of colonization singly was important since the presence of wild-type 
organism influenced clearance of attenuated mutants from the host, and suggested 
enhanced rates of clearance.  In non-competitive experiments, deletion mutants exhibited 
different rates of clearance from mice.  The rough mutants, BA?manBA and 
BM?manBA, were significantly attenuated by 2-3 logs as quickly as 1 week post-
infection but requiring 5 weeks post-infection to be undetectable.  The virB2 mutants,  
BA?virB2 and BM?virB2, cleared at a more gradual rate than the manBA deletions, 
suggesting that their defect in survival occurs at a later stage of infection.  Lastly, 
BA?asp24 and BM?asp24 cleared from mice at a greatly delayed rate, with BA?asp24 
(between 8 and 10 weeks post-infection) and BM?asp24 (after 16 weeks), suggesting 
that Asp24 is only required for persistence of the organism.  The differences in survival 
 84
exhibited by these mutants favored their use in evaluating the correlation between 
protection and persistence of the vaccine strain. 
Protection against homologous challenge (i.e. identical vaccine and challenge 
species) was most successful with the persistent BA?asp24 and BM?asp24 mutants.  
These mutants protected mice against infection at or near sterile levels at all timepoints 
examined, most of which were well past the time of vaccine clearance.  We consider 
these mutants to be the best candidates for novel live vaccine strains, particularly since 
they protect mice better than presently utilized vaccine strains.  BA?virB2, BM?virB2, 
BA?manBA, and BM?manBA, although providing significant levels of immunity, did 
not protect mice from homologous challenge as well as the ?asp24 mutants or currently 
available vaccine strains.  However, the rapid clearance of these mutants enhances their 
safety, and may support their use if delivered using controlled release where the duration 
and presentation to the host can be extended to improve efficacy. 
In protection studies against heterologous challenge, both BA?asp24 and 
BM?asp24 again protected mice significantly against challenge, just barely above the 
limit of detection in both situations.  These results suggest that survival beyond 8-10 
weeks does not enhance protection, and since prolonged survival may have side-effects, 
the use of BA?asp24 as a vaccine strain may be sufficient.  BM?virB2 afforded better 
protection against 2308 challenge than BA?virB2 afforded against 16M challenge.  
These data indicate that vaccination of animals with BAV2 may not protect against a B. 
melitensis exposure, which is possible in the event of a bioterrorist attack or exposure 
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from infected small ruminant species (such as goats).  In this situation, ?virB mutants 
may not be sufficient to protect the host from more than one species of Brucella. 
The degree of protection afforded by different mutant types as vaccine candidates 
was compared with the cytokine profiles elicited from splenocytes both before and after 
challenge in order to characterize any direct correlated of protective immunity.  This 
method was used to evaluate the long-term immune response and mimics field 
conditions, where animals are vaccinated and at some unknown period are exposed to 
wild-type organism, and subsequently mount a memory response.  
IFN-gamma, a Th1 cytokine involved in pathogen clearing from activated 
macrophages, is well defined as an important factor for controlling Brucella abortus 
infections in mice.  IFN-gamma is well documented as an aid to control infection 
through activation of macrophages against intracellular bacteria and protozoa (5, 33, 56).  
Infection in mice is more severe when the animals are treated with antibody to IFN-
gamma, and brucellosis becomes a fatal infection in IFN-gamma knockout mice.  This 
data suggests that IFN-gamma is critical in the early stages of infection (5, 50, 51, 56).  
Since IFN-gamma has been shown to be a strong component of the host immune 
responses against Brucella infections, it was necessary to evaluate the production 
elicited by the different mutant strains.  
The importance of IFN-gamma in controlling infection is confirmed by the data 
presented here.  The best protection was provided by the mutant that elicited the 
strongest IFN-gamma response, BM?asp24.  Both before and after challenge, the levels 
of this cytokine produced by splenocytes remained very high.  For BA?asp24, 
 86
BA?virB2, and BM?virB2 IFN-gamma production was high in mice before challenge 
when stimulated in vitro, reflecting a memory response and correlating with subsequent 
protection against challenge.  When the mice were challenged, however, it is possible 
that in these groups, where the vaccine strain had cleared approximately 10 weeks before 
challenge, that the memory T cells left the spleen for general circulation in response to 
the infection.  It is known that mice infected with S19 or 2308 experienced depletion of 
splenic lymphoid tissue when examined histologically, with decreased percentages of 
splenic T cells (24).  It is possible that culturing splenocytes one week post- challenge to 
stimulate an in vitro response will not reflect what is observed when mice are vaccinated 
solely.  Mice that were vaccinated with RB51 for 6 weeks produced high levels of IFN-
gamma, but the levels dropped after challenge for one week with 2308, which was 
consistent with these results for smooth mutants (57).  IFN-gamma was not induced 
significantly in mice vaccinated with a rough mutant, BM?manBA, and the levels 
remained unchanged before and after challenge.  It is important to note, however, that 
RB51 and manB mutants contain different defects in LPS, correlating with improved 
protection from RB51 as compared to manB vaccination in mice, which may account for 
the observed differences in cytokine profiles (13, 48, 69).   
IL-10 is chiefly an anti-inflammatory molecule that may aid in the control of 
negative effects due to pro-inflammatory cytokines, such as IFN-gamma (71).  IL-10 is 
actually produced as part of a Th2 response, but may be involved in negative feedback 
control of B. abortus induced cytokine secretion, such as IL-12.  For many organisms, it 
affects the Th1 response by down-regulating IL-12 affinity receptors thus decreasing 
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IFN-gamma (5, 26).  For Brucella, IL-10 does not seem to down-regulate IFN-gamma 
production, however.  Perhaps for this disease, the effect of IL-10 on the immune 
response is not counterbalance the production of Th1 cytokines, but rather to limit 
exaggerated pro-inflammatory responses of the host.  IL-10 is known to help limit the 
extent and strength of inflammatory responses (71).  Since BALB/c mice are known to 
mount a very strong inflammatory response early in infection, Th2 cytokines such as IL-
10 are necessary to prevent overwhelming the host (5, 57).  This might also benefit the 
host by limiting the influx of phagocytic cells and potential spread of the disease, though 
this would not necessarily benefit the bacteria.  Recently, it has been shown that IL-10 
develops pro-inflammatory qualities during active inflammatory responses (71).  The 
fact that IL-10 was generally increased after challenge in these experiments may suggest 
an attempt of the host to down-regulate the inflammatory response that is normally 
induced by Brucella.  IL-10 knockout mice do not tolerate B. abortus infection well, also 
demonstrating its importance in down-regulating the pro-inflammatory response (33).  
Levels of IL-10 in mice vaccinated with asp24 mutants increased after challenge, similar 
to levels of IL-10 in naïve mice challenged with wild type organism.  This suggests that 
the asp24 deletions elicit similar biologic effects as wild type organism, and may explain 
the superior protection afforded by these strains. 
Surprisingly, IL-12 was not detected from any of the infected splenocytes 
stimulated with heat killed Brucella except for naïve mice challenged with 16M.  IL-12 
plays a pivotal role in the immune cascade after its release from macrophages, including 
activation and differentiation of NK cells, and T and B cells.  B. abortus produced IL-12 
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p40 in human monocytes, as well as in mouse models (33, 57). It is important to note 
that for these experiments, culture supernatants were collected at three days post-
stimulation.  It is possible that this timepoint is not optimal for the detection for certain 
cytokines, which may be produced either rapidly or late in vitro.  The same results were 
observed for IL-2 and IL-4.  IL-4, however, is typically upregulated when mice are not 
infected with living bacteria, but rather soluble Brucella proteins or heat killed bacteria, 
so this result may not be surprising (82). 
Another possible explanation for the data is that due to the experimental 
timepoints chosen, the mice were vaccinated for longer periods of time than have been 
looked at in the past.  Numerous studies have considered the effect of Brucella infection 
on cytokine production and immune response, but none have looked at time points as 
late as 20 weeks, but rather much earlier in infection (26, 39, 50, 57, 72).  In cases of 
acute human brucellosis, patients also display a Th1-type response similar to the 
previous mouse studies, producing IFN-gamma and IL-2; patients experiencing chronic 
infections do not.  The diminished Th1 response as Brucella infection progresses may 
explain the establishment of chronic infections (31).  It has also been demonstrated that 
chronic brucellosis is accompanied by a significant, general immunosuppression (29, 31) 
therefore persistent mutants whose attenuation isn’t marked compared to wild-type until 
later in mouse infections (typically greater than 8 weeks), and could possibly be 
considered a more chronic infection, may not display a strong Th1 response.  In this 
study, mice were vaccinated for 20 weeks, and it is very possible that the numbers of T 
cells were diminished or virtually non-existent, and so we would not see the “typical” 
 89
immune pattern previously published for acute mouse models of infection:  Th1, with 
up-regulation of IFN-gamma, IL-2, and IL-12.  Since previous research has never 
considered such late time points in the mouse, direct comparisons can not be made.  
Overall, the mouse has proven to be a sensitive and popular model for evaluating 
brucellosis.  Since the virulence of Brucella is linked to its ability to survive in 
macrophages, as it is able to do in the mouse model, virulence in other animal hosts such 
as ruminants can be predicted.  In addition, this model has proved invaluable for 
characterization of genetic components necessary for virulence, as well as an affordable 
and consistent method for evaluation of potential vaccine candidates, by assessment of 
mutant survival (23, 28, 38).  The mouse model cannot be used, however, to gauge the 
effect of persistence on the colonization of reproductive tissues, thus the need for a 
natural ruminant model after the initial murine screen.  Since the mouse is not an 
accurate model of disease in target species, vaccine candidates from the mouse will need 
to be re-evaluated in a suitable ruminant model.  The asp24 deletion mutants were the 
most protective in the mouse screen against both homologous and heterologous 
challenge infections, and perhaps their protective ability in target ruminants may be 
superior to the other candidates in that model as well.  
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SAFETY AND EFFICACY OF UNMARKED MUTANTS IN THE PREGNANT 
GOAT MODEL 
 
INTRODUCTION 
Experimental infections of the goat with B. abortus S2308 result in disease 
similar to cattle, regarding clinical symptoms, distribution of the organism within the 
reticuloendothelial and reproductive systems, and serological responses (47).  Infection 
with S2308 in the goat is not efficiently reproducible.  Pregnant dams abort 30-50% of 
the time and dam/kid pairs are colonized approximately 50-70% of the time.  In contrast, 
pregnant goats experimentally inoculated with B. melitensis 16M abort fetuses 70-100% 
of the time, with 90-100% of the dam/kid pair colonized.  In artificially controlled 
infection of goats, 16M therefore elicits a more reproducible experimental effect.  This 
effect directly mimics field infection, since pregnant goats naturally infected with B. 
melitensis often abort in the last trimester of pregnancy (21).  
The vaccine currently used in goats is Rev 1, a 16M derivative whose genetic basis 
for attenuation is undefined.  Rev 1 may induce abortions if administered to a pregnant 
goat and does not prevent spread of the disease in flocks endemically infected prior to 
vaccination (19).  This vaccine does, however, protect approximately 80-100% of goats 
from abortion and colonization of dam/kid pairs after challenge with wild-type 16M in 
an experimental setting, and therefore Rev 1 is a model vaccine to compare protection 
provided by novel vaccine strains, and improved levels of safety (21).  
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For all these reasons, the goat model is useful for evaluating the in vivo phenotype of 
various mutants, by comparing abortions caused by infection with attenuated unmarked 
deletions to the wild-type 16M, thus assessing their degree of virulence.  The response of 
the pregnant goat to vaccination with attenuated 16M mutants is therefore a sensitive 
model to evaluate safety of the mutant for use as a vaccine in some target species. 
The caprine model of brucellosis (or Brucella infection) is well documented, offering 
many advantages over the murine model to assess attenuation of mutants in a ruminant 
species (3, 19, 21, 47).  For example, more goats can be used in restricted spaces due to 
their smaller size, they cost less than larger ruminants, and the gestation period is only 
approximately five months as compared to nine in the cow, and therefore results are 
more timely.  In addition, the conjunctival route of inoculation mimics the natural route 
of infection, allowing the bacteria to invade mucosal sites (21).  
 
MATERIALS AND METHODS 
The pregnant goat model of pathogenesis.  To compare the pathogenesis of 
BM?cydBA, BM?asp24, and BM?virB2 to the virulent parental strain 16M, 4 groups of 
6 each pregnant female goats averaging 110 days of gestation were infected at 1X107 
CFU/ml by placing 50 μl of either 16M or the three selected 16M unmarked deletion 
mutants into each conjunctival sac.  This challenge dose is commonly used and has 
demonstrated consistent abortion and colonization in the goat (21).  Animals were 
monitored daily; birth status was recorded as aborted fetuses or live kid(s).  Serum 
samples were collected prior to vaccination and at necropsy for serological studies.  The 
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fetuses were necropsied with samples of lung, liver, spleen, and abomasal fluid collected 
for bacteriology and histology.  Approximately 30 days after delivery, all dams were 
euthanized and necropsied; samples of liver, spleen, mammary gland, supramammary 
lymph nodes, and parotid lymph nodes were collected for bacteriology and 
histopathology. 
 
Culturing of tissues.  For primary isolation of Brucella from tissues, a piece of 
the tissue to be cultured was washed in 70% ethanol and flamed to remove external 
contaminants.  The tissue was then sliced open, and the cut surface was macerated with a 
sterile scalpel.  The macerated tissue surface was then streaked across the surface of a 
Farrell media plate (25).  All tissue-inoculated plates were incubated for up to ten days 
to detect the presence of Brucella.  Positivity is based upon a scale of plus or minus, with 
isolation of ?1 CFU per plate determining the tissue to be positive. 
 
Biotyping.  All colonies arising on Farrell’s media from bacteriology were first 
identified by size, shape, and color, to be consistent with Brucella.  Colonies were also 
Gram stained to ensure that they are gram-negative coccobacilli, also consistent with 
Brucella.  Isolates were then biotyped as per the standard biotyping protocols.  This 
included growth on dyes, including thionin and basic fuchsin, hydrogen sulfide 
production, carbon dioxide requirements, growth on erythritol, lysis by phage, and 
agglutination by monospecific sera.  These tests were completed to ensure the colonies 
were modified B. melitensis biovar 1. 
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Immune responses in the pregnant goat.  Serum samples were collected from 
goats at several timepoints post-infection.  Approximately 10 ml of blood was collected 
into vacutainers without additive, allowed to clot overnight, and then and spun at 1700 x 
g for 25 minutes at room temperature.  Serum was decanted into a 15ml conical tube for 
testing and subsequent freezing.  Brucella card tests (USDA Ames, Iowa) were 
performed on the serum samples to determine seroconversion. 
Enzyme-linked immunosorbent assays (ELISAs) were preformed on serum 
samples collected at various times post-infection to detect the IgG response of infected 
goats.  Ninety six well plates were coated with 100μl of 1μg/ml Brucella lysate.  Lysate 
was prepared from heat killed liquid cultures of 16M (approximately 4 x 1010 CFU, 
washed in PBS) by sonication.  Protein concentration was determined to be 10μg/ml 
using BioRad Protein Assay Reagent as described by the manufacturer.  A 1:10,000 
dilution of the bacterial lysate in carbonate buffer was used to coat the wells overnight at 
4°C.  Wells were blocked for three hours with 300μl 3% gelatin (w/v) in PBS, and then 
plates were washed three times with PBS to remove residual blocking buffer.  For pre-
bleeds, goat sera was first diluted 1:8 with 0.3% gelatin (w/v) in PBS-T, and then added 
to the first well of each row (A through H) and 2-fold serially diluted across the plate in 
successive wells.  For post-vaccination samples, sera were diluted to 1:128 and then two-
fold serial dilutions were prepared as described above.  Following a one-hour incubation, 
the wells were washed three times with PBS-T to remove all traces of sera.  Peroxidase 
labeled rabbit anti-goat IgG (H+L) secondary antibody (KPL) was added at a 1:2500 
dilution (0.2 μg/ml) in 100μl PBS-T per well, and the plates were rocked for 1 hour at 
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room temperature.  The wells were washed seven times with PBS-T to remove any 
residual secondary antibody.  ABTS (Sigma) substrate was added at 100μl per well 
according to the manufacturer’s protocol, and color development continued at room 
temperature for 10-15 minutes before the reaction was stopped with 100μl 1% SDS 
(w/v).  The samples were read at 405 nm using a visible wavelength spectrophotometer. 
Cut-off values for ELISA were established first with known negative goat 
samples.  Cut-off values were determined to be the fifth two fold serial dilution (1:32), 
which was the first dilution where changes in OD values were detectable that would be 
above background.  Baseline titers were therefore set at a value of 5.  Titers for samples 
were based upon the first dilution in the series that the OD reading was below the cut-off 
OD value.  The IgG levels are therefore represented by the two fold increases in IgG 
levels over the duration of infection. 
 
Histology.  Samples of all tissues collected from both the dams and kids were 
fixed in 10% buffered formalin, trimmed with a scalpel so that they fit into tissue 
cassettes.  Tissues were paraffin embedded and stained with a routine H&E stain by the 
Histology lab at the Texas A&M College of Veterinary Medicine.  Histological 
differences of the H&E slides were microscopically assessed by ACVP Board Certified 
pathologist Dr. L. Garry Adams to determine differences between vaccine groups. 
 
Vaccination efficacy.  Mature non-pregnant goats were vaccinated in groups of 
eight with either 1x109 CFU unmarked 16M deletion mutant, saline or 1x106 CFU Rev 1 
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vaccine strain.  Four weeks after vaccination, dams were housed with males and allowed 
to breed.  Pregnancy was confirmed via ultrasound, and at approximately 110 days of 
gestation, dams were challenged with 1x107 CFU in 100μl 16M via bilateral 
conjunctival inoculation.  At birth, the status of the kid(s) was recorded as live, weak, 
born live but found dead, or dead on arrival, and samples of spleen and abomasal fluid 
were collected for bacteriology.  Within 14 days of delivery, dams were euthanized; 
samples of liver, spleen, mammary gland, parotid lymph node, and supramammary 
lymph node were collected and cultured (19, 21).  Serum samples were collected at 
vaccination, five weeks post-vaccination, at the date of challenge (18 weeks post-
vaccination), and at necropsy (7 weeks post-challenge) for serological studies.  
Protection due to vaccinations with mutant strains was compared to protection conferred 
by Rev-1 vaccine strain. 
 
RESULTS 
Pilot goat safety study.  The first set of pregnant goat safety experiments to 
determine safety of unmarked deletion mutants in pregnant animals were held at Texas 
A&M University in the spring of 2002.  Goats were divided into four different treatment 
groups: (a) 10-16M inoculated (b) 10-BM?virB2 inoculated, (c) 10-BM?cydBA 
inoculated, or (d) 10-uninfected controls.  The purchased goats were to arrive at 
approximately 90-100 days of gestation.  Several goats gave birth prior to arrival, and 
one immediately delivered after arrival.  Those goats were moved to the unchallenged 
control group.  Overall, the majority of goats were well past 110 days of gestation at the 
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day of infection, and as such, accurate assessments of abortion and safety could not be 
determined (Figs.  36, 37, and 38).  All goats were necropsied for bacterial isolation 
from tissues (Tables 5 and 6).  Isolation of ?1 CFU Brucella from any goat tissue 
assigned that animal as positive.  Goats were also bled weekly to detect Brucella-
specific antibodies by card test from exposure to the vaccine strain. 
In the 16M challenged group, several goats were culture positive (#9, 32, and 
51).  One kid was culture positive as well in all organs tested (#51-A).  These isolates 
were cultured for isolation directly from the tissue; this one-passage isolate was frozen 
for the lab’s future virulent 16M stock.  The acquisition of the virulent fetal isolate was a 
vital asset to the lab for future experimentation and mutant production. 
The biohazard buildings were useful for containing these experimental goats that 
posed health risks to the human workers due to the presence of Brucella in their tissues.  
None of the staff was accidentally infected, and these buildings will be an excellent 
facility to continue large animal experiments. 
 
Evaluation of vaccine safety.  In the spring of 2003, a goat safety study was 
performed at Louisiana State University (LSU) to determine the safety of unmarked 
deletion mutants in pregnant goats.  Treatment groups included (a) 6-16M inoculated 
goats, (b) 6-BM?asp24 inoculated goats, (c) 6-BM?virB2 inoculated goats, and (d) 6-
BM?cydBA inoculated goats.  Birth statuses of kids or fetuses were recorded by the staff 
at LSU.  The 16M infected group did not demonstrate marked abortions or abnormal 
 97
 
 
 
 
 
 
FIG.  36.  Day of gestation at challenge for 16M treatment group: pilot goat safety.  
Goats were infected with 1x107 CFU 16M conjunctivally in the third trimester of 
pregnancy.  The gestation period of the goat is approximately 150 days, therefore 
subtracting the number of days elapsed since infection from 150 equals the approximate 
stage of gestation at infection.  Bars represent the approximate day of gestation that each 
goat was vaccinated.  The solid line at 110 days represents the target stage of gestation 
for experimental challenge infection.  In this group, 6/10 goats were challenged after the 
target infection period of 110 days +/- 10 days.
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FIG.  37.  Day of gestation at challenge for BM?virB2 treatment group: pilot goat safety.  
Goats were vaccinated with 1x107 CFU unmarked deletion BM?virB2  conjunctivally in 
the third trimester of pregnancy.  The gestation period of the goat is approximately 150 
days, therefore subtracting the number of days elapsed since infection from 150 equals 
the approximate stage of gestation at infection.  Bars represent the approximate day of 
gestation that each goat was vaccinated.  The solid line at 110 days represents the target 
stage of gestation for experimental challenge infection.  In this group, 10/10 goats were 
challenged after the target infection period of 110 days +/- 10 days. 
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FIG.  38.  Day of gestation at challenge for BM?cydBA treatment group: pilot goat 
safety.  Goats were vaccinated with 1x107 CFU unmarked BM?cydBA conjunctivally in 
the third trimester of pregnancy.  The gestation period of the goat is approximately 150 
days, therefore subtracting the number of days elapsed since infection from 150 equals 
the approximate stage of gestation at infection.  Bars represent the approximate day of 
gestation that each goat was vaccinated.  The solid line at 110 days represents the target 
stage of gestation for experimental challenge infection.  In this group, 9/10 goats were 
challenged after the target infection period of 110 days +/- 10 days. 
 
 100 
 
 
 
 
 
TABLE 5.  Culture and card test results from 
pilot goat safety study control groups 
16M    
Goat Number Dam Kid Card Test 
3 - - + 
7 - - + 
9 + - + 
32 + - + 
46 - - + 
48 - - - 
49 - - + 
51 + + + 
52 - - + 
56 - - - 
    
saline    
Goat Number Dam Kid Card Test 
13 - - - 
18 - - - 
19 - - n/a 
34 - - - 
35 - - - 
40 - - n/a 
50 - - - 
54 - - - 
55 - - - 
57 - - - 
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TABLE 6.  Culture and card test results from 
pilot goat safety study B. melitensis mutant groups 
BM?virB2    
Goat Number Dam Kid Card Test 
8 - - n/a 
11 - - - 
15 - - - 
28 - - - 
30 - - - 
33 - - - 
37 - - - 
38 - - - 
39 - - - 
43 - - - 
    
BM?cydBA    
Goat Number Dam Kid Card Test 
1 - - - 
10 - - - 
12 - - - 
14 - - - 
20 - - - 
23 - - - 
25 - - - 
26 - - - 
47 - - - 
53 - - - 
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birth statuses in this study; the challenge stock was from LSU, and was not the virulent 
isolate acquired at Texas A&M (Table 7).  Only 1/8 kids (#28-A) was DOA and 1/8 
(#49-A) was never born.  For BM?cydBA, 3/7 kids were considered questionable birth 
statuses (found dead, or died shortly after birth), and 1/7 was never born (#43-A).  The 
group vaccinated with BM?asp24 experienced the most recorded abnormal birth 
statuses, with 8/8 kids born live but found dead or were DOA.  BM?virB2 vaccinates 
had high numbers of abnormal births as well, with 4/8 dead in utero or born live but 
found dead.  The majority of the kids from both the BM?asp24 and BM?virB2 groups, 
though dead, were not considered abortions by the group at LSU, since the mornings that 
they were born were extremely cold and rainy.  Based on these criteria, the deaths in the 
BM?asp24 and BM?virB2 mutant groups were attributed to the weather and not to the 
infections.  Goats marked with N/A represent dams that were euthanized due to injury or 
illness before parturition.   
In order to obtain objective data, bacteriologic culture of tissues was performed.  
In the 16M infection group, 4/5 dams were culture positive and 3/5 of the corresponding 
kids were positive (Table 8).  Isolation of ?1 CFU Brucella from any goat tissue 
assigned that animal as positive.  Culture positive animals were also seropositive using 
the card test.  The BM?cydBA mutant appeared to be as virulent in the pregnant goat 
model as wild-type 16M.  In the BM?cydBA group, 5/6 of the dams were culture and 
card test positive, and 4/6 of the kids were positive.  It was for this reason that the cydBA 
mutants were dropped from the mouse studies, since the 2003 goat efficacy study  
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TABLE 7.  Birth status of goats from the 2003 safety study 
16M Birth Status  BM?asp24 Birth Status 
#9 2 live  #8  2 BLFD 
#28 1 DOA  #12 1 BLFD 
#29 2 live  #15 1 DOA 
#46 N/A  #35 2 BLFD 
#48 2 live  #45 1 BLFD 
#49 Not born  #47 1 BLFD 
     
     
BM?cydBA Birth Status  BM?virB2 Birth Status 
#1 1 BLFD  #4 1 born live 
#17 2 live  #5 2 born live 
#22 1 live, 1 BLFD  #7 1 live, 1BLFD 
#26 N/A  #13 1 dead in utero 
#32 1 BLFD  #23 2 DOA 
#43 Never gave birth  #44 N/A 
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TABLE 8.  Culture and card test results for the 2003 goat 
  safety study 
16M Recovered Dam Kid Card Test 
#9 - - - 
#28 + + + 
#29 + - + 
#48 + + + 
#49 + + n/a 
    
BM?virB2 Recovered Dam Kid Card Test 
#4 - - - 
#5 - - - 
#7 - - - 
#13 - - - 
#23 - - - 
#44 - - - 
    
BM?cydBA Recovered Dam Kid Card Test 
#1 + + + 
#17 - + + 
#22 + + + 
#26 + + + 
#32 + - + 
#43 + - n/a 
    
BM?asp24 Recovered Dam Kid Card Test 
#8 + - + 
#12 + - + 
#15 + - + 
#35 - - - 
#45 + - - 
#47 + - + 
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occurred first.  The cydBA mutants will not be improved vaccine candidates since they 
are not safe in pregnant goats.  The BM?virB2 mutant did not colonize any of the 
maternal or fetal tissues and did not cause seroconversion.  BM?virB2 was therefore 
considered an improved vaccine strain for efficacy trials since it was safe in pregnant 
goats.  The BM?asp24 mutant showed the most interesting phenotype in the pregnant 
goats.  Though it was able to colonize maternal tissues (5/6) and cause seroconversion 
(4/6), it was not cultured from any of the fetal tissues.  The maternal phenotype in goats 
was not surprising, since the mutant does persist in mice for extended periods.  The 
inability of BM?asp24 to colonize fetal tissues makes it a superior vaccine candidate to 
consider for efficacy trials, since it is considered safe for pregnant goats.  The absence of 
Brucella from these groups of kids also corroborated the birth statuses as being normal 
though many of these kids had died. 
 
Serologic responses in the goat safety study.  The IgG titers of the goat 
samples as determined by ELISA confirmed the card tests, but were more specific since 
relative titers could be assigned, whereas the card test only provided positive or negative 
results.  The results for 16M, BM?cydBA, and BM?asp24 indicate a spread of IgG titers 
between animals within each group that was indistinguishable from group to group 
(Figs.  39, 40, and 41).  The BM?virB2 group (Fig.  42) did not have elevated levels of 
IgG, which was consistent with the negative card test results and elevated attenuation 
caused by this defect (Table 8).
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FIG.  39.  2003 safety study: IgG titers of goats challenged with 16M.  Goats were 
vaccinated with 1x107 CFU 16M conjunctivally at 110 +/- 10 days gestation.  Goats 
were bled at two timepoints; one pre-bleed sample before challenge and one sample 
eight weeks post-challenge.  Serum samples were assayed via ELISA to detect IgG 
antibodies due to the vaccination.  Baseline titers were set at 5 as described in the text.  
Titers for samples were based upon the first dilution in the series that the OD reading 
was below the cut-off OD value.  The IgG levels are therefore represented by the two 
fold increase in IgG levels over the duration of infection. 
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FIG.  40.  2003 safety study: IgG titers of goats vaccinated with BM?asp24.  Goats were 
vaccinated with 1x107 CFU unmarked BM?asp24 conjunctivally at 110 +/- 10 days 
gestation.  Goats were bled at two timepoints; one pre-bleed sample before challenge 
and one sample eight weeks post-challenge.  Serum samples were assayed via ELISA to 
detect IgG antibodies due to the vaccination.  Baseline titers were set at 5 as described in 
the text.  Titers for samples were based upon the first dilution in the series that the OD 
reading was below the cut-off OD value.  The IgG levels are therefore represented by the 
two fold increase in IgG levels over the duration of infection. 
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FIG.  41.  2003 safety study: IgG titers of goats vaccinated with BM?cydBA.  Goats 
were vaccinated with 1x107 CFU unmarked BM?cydBA conjunctivally at 110 +/- 10 
days gestation.  Goats were bled at two timepoints; one pre-bleed sample before 
challenge and one sample eight weeks post-challenge.  Serum samples were assayed via 
ELISA to detect IgG antibodies due to the vaccination.  Baseline titers were set at 5 as 
described in the text.  Titers for samples were based upon the first dilution in the series 
that the OD reading was below the cut-off OD value.  The IgG levels are therefore 
represented by the two fold increase in IgG levels over the duration of infection. 
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FIG.  42.  2003 safety study: IgG titers of goats vaccinated with BM?virB2.  Goats were 
vaccinated with 1x107 CFU unmarked BM?virB2 conjunctivally at 110 +/- 10 days 
gestation.  Goats were bled at two timepoints; one pre-bleed sample before challenge 
and one sample eight weeks post-challenge.  Serum samples were assayed via ELISA to 
detect IgG antibodies due to the vaccination.  Baseline titers were set at 5 as described in 
the text.  Titers for samples were based upon the first dilution in the series that the OD 
reading was below the cut-off OD value.  The IgG levels are therefore represented by the 
two fold increase in IgG levels over the duration of infection. 
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Histological changes resulting from exposure to vaccine strains.  Tissues 
collected at time of necropsy were assessed for histological changes due to the vaccine 
strain or from wild-type 16M.  Degree of pathology was graded on a scale of 0 to 4, with 
zero representing no marked change and four being the most marked.  For each animal, 
various samples were evaluated and for each tissue, various criteria were considered. 
Goats infected with 16M had a great deal of pathology associated with both 
maternal and fetal tissues.  For the dams, there was a moderate to high degree of activity 
(B and T cell) in the parotid lymph nodes (PLN) and supramammary lymph nodes 
(SMLN) (Table 9).  There was mild pathology in the livers, some degree of activity in 
the splenic nodules, and a moderate degree of inflammation in the mammary glands 
(MG).  The kids experienced a moderate to high degree of B and T cell activity in the 
spleen (Table 10).  The lungs portrayed a moderate degree of hemorrhage and a varied 
degree of inflammation, primarily mononuclear.  The liver pathology was varied, but 
there was an overall moderate inflammation in the portal triad and sinusoidal areas. 
Goats infected with BM?cydBA had, on average, marked pathological changes in their 
tissues (Table 11).  Dams had mild to moderate B and T cell expansion in the PLNs and 
SMLNs.  In the mammary glands, a high degree of inflammation was evident, with 3/5 
dams having early microgranuloma formation.  There was overall low pathology in the 
spleen except for a moderate to high degree of hemorrhage primarily in the PLNs, as 
well as low pathology in the livers.  Spleens of kids had moderate to high B and T cell 
expansion (Table 12).  Some kids had high degrees of congestion in the lungs with 
hemorrhage, and some with inflammatory cells in the liver.
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TABLE 9.  Histologic changes of pregnant goats infected with 16M   
Dam # 
Changes in 
Spleen Changes in Liver 
Changes in 
Parotid Lymph 
Node 
Changes in 
Supramammary 
Lymph Node 
Changes in 
Mammary Gland 
#9 1 activity in 
nodules 
1 hemorrhage   
PLNs 
0 sinusoidal 
hyperplasia 
0 congestion 
0 congestion 
0 mononuclear 
portal 
inflammation 
 
2 B cell 
expansion 
3 T cell 
expansion 
1 histiocytosis 
3+ B cell 
expansion 
1 T cell 
expansion 
Lactating 
 
1+ mononuclear 
inflammation 
#28 
 
2 activity in 
nodules 
2 hemorrhage 
PLNs 
1 sinusoidal 
hyperplasia 
0 congestion 
1 congestion 
1 mononuclear 
portal 
inflammation 
 
 
 
4 B cell 
expansion 
1 T cell 
expansion 
0 histiocytosis 
 
 
4 B cell 
expansion 
1 T cell 
expansion 
2 sinusoidal 
histiocytosis 
 
minimal lactation 
 
4+ mononuclear 
inflammation 
 
 
 
#29 1 activity in 
nodules 
2 hemorrhage 
PLNs 
(excessive 
PMN and 
hemorrhage) 
1 sinusoidal 
hyperplasia 
0 congestion 
0 congestion 
1 mononuclear 
portal 
inflammation 
4 B cell 
expansion 
1 T cell 
expansion 
1 histiocytosis 
 
 
 
 
 
4+ B cell 
expansion 
2+ T cell 
expansion 
2+ sinusoidal 
histiocytosis 
(active) 
 
 
 
minimal lactation 
 
4 inflammation 
(early 
microgranuloma) 
 
 
 
 
 
#46 0 activity in 
nodules 
0 hemorrhage 
PLNs 
1 sinusoidal 
hyperplasia 
(lymphoid 
depletion) 
4 congestion 
0 congestion 
0 mononuclear 
portal 
inflammation 
 
4 B cell 
expansion 
1 T cell 
expansion 
1 histiocytosis 
4+  B cell 
expansion 
4 T cell 
expansion 
1 sinusoidal 
hyperplasia 
 
 
 
mild lactation 
 
2 mononuclear 
inflammation 
(PMNs) 
 
 
 
 
#48 1 activity in 
nodules 
2 hemorrhage 
PLNs 
0 sinusoidal 
hyperplasia 
4 congestion 
0 congestion 
1 portal 
mononuclear 
inflammation 
N/A 1 B cell 
expansion 
0 T cell 
expansion 
1 sinusoidal 
hyperplasia 
4 mononuclear 
inflammation 
#49 3 activity in 
nodules 
1 hemorrhage 
PLNs 
0 sinusoidal 
hyperplasia 
4 congestion 
0 congestion 
1 portal 
mononuclear 
inflammation 
 
1 B cell 
expansion 
1 T cell 
expansion 
0 histiocytosis 
1 B cell 
expansion 
0 T cell 
expansion 
0 sinusoidal 
histiocytosis 
N/A 
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TABLE 10.  Histologic changes of goat fetuses infected with 16M   
Kid or fetus # Changes in Spleen Changes in Lung  Changes in Liver 
#9A (immature) 1 atelactasis 
5 congestion 
2 hemorrhage 
2 inflammation (90% 
mononuclear) 
5 congestion 
4 hemorrhage 
1 inflammation (mild 
sinusoidal accumulation 
of mononuclear cells) 
#9 B 1-2 congestion 
3 B cell expansion  
1 T cell expansion 
0 sinusoidal hyperplasia 
3 atelactasis 
1 congestion 
4 hemorrhage 
1 inflammation (90% 
mononuclear) 
1 congestion 
0 hemorrhage 
0 inflammation 
#28 A 1 congestion 
2 B cell expansion 
3 T cell expansion 
2 sinusoidal hyperplasia 
1 atelactasis 
4 congestion 
4 hemorrhage  
3-4 inflammation (50-50) 
0 congestion 
0 hemorrhage 
3 inflammation (mild 
sinusoidal and marked 
portal triad 
mononuclear-
macrophage infiltrate) 
#29 A 0 congestion 
2 B cell expansion 
3 T cell expansion 
2 sinusoidal hyperplasia 
2 atelactasis 
2 congestion 
2 hemorrhage 
1 inflammation (90% 
mononuclear) 
0 congestion 
0 hemorrhage 
1 inflammation (mild 
mononuclear infiltration 
of portal triad 
#29 B 0-1 congestion 
2 B cell expansion 
4 T cell expansion 
0 sinusoidal hyperplasia 
1 atelactasis 
1 congestion 
1 hemorrhage 
2 inflammation (99% 
mononuclear) 
N/A 
#48 A 0 congestion 
4 B cell expansion 
4 T cell expansion 
0 sinusoidal hyperplasia 
4 atelactasis; pleural and 
interlobular edema 
0 congestion 
0 hemorrhage  
0 inflammation 
N/A 
#48 B 0 congestion 
1 B cell expansion 
3 T cell expansion 
0 sinusoidal hyperplasia 
3 atelactasis 
1 congestion 
2 hemorrhage 
1 inflammation 
(mononuclear) 
0 congestion 
0 hemorrhage 
3 inflammation; early 
sinusoidal  
microgranuloma 
formation 
#49 A 1 congestion 
2 B cell expansion 
3 T cell expansion 
0 sinusoidal hyperplasia 
4 atelactasis  
0 congestion 
1 hemorrhage  
1 inflammation 
0 congestion 
0 hemorrhage 
1 inflammation; mild 
mononuclear portal 
infiltration 
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TABLE 11.  Histologic changes of pregnant goats infected with BM?cydBA 
Dam # 
Changes in 
Spleen 
Changes in 
Liver 
Changes in 
Parotid Lymph 
Node 
Changes in 
Supramammary 
Lymph Node 
Changes in 
Mammary Gland 
#1 0 congestion 
3 activity in 
nodules 
0 sinusoidal 
hyperplasia 
3 hemorrhage 
PLNs 
0 congestion 2 B cell 
expansion 
3 T cell 
expansion 
0 histiocytosis 
3+ B cell 
expansion 
1 T cell 
expansion 
0 sinusoidal 
histiocytosis 
Lactation 
 
3+ mononuclear 
inflammation 
#17 0 congestion 
0 activity in 
nodules 
0 sinusoidal 
hyperplasia 
0 hemorrhage 
PLNs 
1 congestion 0 B cell 
expansion 
0 T cell 
expansion 
0 histiocytosis 
1 B cell 
expansion 
0 T cell 
expansion 
1 sinusoidal 
histiocytosis 
minimal lactation  
 
0 mononuclear 
inflammation1 
foamy milk 
granuloma 
#22 0 congestion 
2 activity in 
nodules 
0 sinusoidal 
hyperplasia 
2-3 hemorrhage 
PLN 
1 congestion 2 B cell 
expansion 
0 T cell 
expansion 
0 histiocytosis 
N/A minimal lactation 
2 mononuclear 
inflammation 
mononuclear, 
early granuloma 
formation 
#26 0 congestion 
1 degree of 
activity in 
nodules 
1 sinusoidal 
hyperplasia 
1 hemorrhage 
PLN 
1 congestion 1 B cell 
expansion 
0 T cell 
expansion 
0 histiocytosis 
 
3+ B cell 
expansion  
1+ T cell 
expansion 
1 sinusoidal 
histiocytosis 
heavy lactation 
#32 1 congestion 
1 activity in 
nodules  
0 sinusoidal 
hyperplasia 
2 hemorrhage 
PLN: 
excessive 
PMN and 
hemorrhage 
1 congestion 0 B cell 
expansion 
0 T cell 
expansion 
0 histiocytosis 
1 B cell 
expansion  
1 T cell 
expansion 
4 sinusoidal 
histiocytosis 
4+ mononuclear 
inflammation, 
early 
microgranuloma 
formation 
(PMNs at 1) 
#43 4+ congestion 
2 degree of 
activity in 
nodules: 
inflammatory 
1 congestion 3 B cell 
expansion 
1 T cell 
expansion 
0 histiocytosis 
2 B cell 
expansion 
1 T cell 
expansion 
2 sinusoidal 
histiocytosis 
N/A 
 114 
 
 
 
TABLE 12.  Histologic changes of goat fetuses infected with BM?cydBA 
Kid or fetus # Changes in Spleen Changes in Lung Changes in Liver 
#1A 0-1 congestion 
2+ B cell expansion 
1+ T cell expansion 
0 sinusoidal 
hyperplasia 
2-3 atelactasis 
4 congestion 
5 hemorrhage 
1 inflammation (99% 
mononuclear 
accumulation in septal 
capillaries) 
2 congestion 
#17A 1 congestion 
1 B cell expansion 
3-4 T cell expansion 
2 sinusoidal 
hyperplasia 
4-5 atelactasis,  
2-3 congestion 
0 hemorrhage 
0 inflammation 
0 congestion 
0 inflammation 
#17B 1 congestion 
3 B cell expansion 
2 T cell expansion 
1-2 sinusoidal 
hyperplasia 
2 atelactasis  
0 congestion 
0 hemorrhage 
0 inflammation 
0 congestion 
0 inflammation 
#22A 2 congestion 
3 B cell expansion 
1 T cell expansion 
0 sinusoidal 
hyperplasia 
1 atelactasis (alveolar 
rupture marked) 
0 congestion 
1 hemorrhage 
0 inflammation 
0 congestion 
0 inflammation 
#22B 1 congestion 
2 B cell expansion 
3 T cell expansion 
1 sinusoidal 
hyperplasia 
1 atelactasis (alveolar 
rupture marked) 
0 congestion 
1 hemorrhage 
0 inflammation 
0 congestion 
0 inflammation 
#32A 1 congestion 
3-4 B cell expansion 
1 T cell expansion 
1 sinusoidal 
hyperplasia 
0 congestion 
1 hemorrhage; marked 
agonal emphysema 
0 inflammation 
 
0 congestion 
2 portal triad 
inflammation 
(mononuclear) 
1  sinusoidal 
inflammation 
#43A 2-3 congestion 
3 B cell expansion 
3 T cell expansion 
1 sinusoidal 
hyperplasia 
0 atelactasis  
0 congestion 
3-4 hemorrhage 
0 inflammation 
0 congestion 
2-3 portal mononuclear and 
neutrophilic infiltrate; 
sinusoidal mononuclear 
#43B 1 congestion 
3 B cell expansion 
3 T cell expansion 
0 sinusoidal 
hyperplasia 
0 atelactasis 
0 congestion 
1 hemorrhage 
0 inflammation 
0 congestion 
4 sinusoidal 
microgranulomas 
around THV 
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Goats infected with BM?asp24 overall showed low histological changes in the 
PLNs, livers, and spleens (Table 13).  In the SMLN and mammary gland, however, there 
were numerous changes, with moderate to high inflammation in the MG (primarily 
mononuclear) and very high activity of B and T cells in the SMLN.  Kids overall had 
moderate B and T cell expansion in the spleen with mild congestion, few changes in the 
livers, and mild congestion in the lungs with low levels of inflammation or hemorrhage 
(Table 14).  
Goats infected with BM?virB2 showed low overall histological change 
associated with the vaccination.  Dams had no significant change in the livers or spleens, 
mild B and T cell expansion in lymph nodes and spleens, and only mild inflammation in 
the mammary gland (Table 15).  Tissues of kids showed moderate B and T cell 
expansion in spleens, very mild degree of congestion for some livers, and mild 
hemorrhage and mononuclear inflammation in the lungs (Table 16). 
 
Vaccine efficacy study.  Efficacy studies were performed at LSU in the fall of 
2003, comparing a vaccine strain, Rev1, with safe unmarked vaccine candidates 
BM?asp24, BM?virB2, and saline as a negative control.  Goats were bled prior to 
vaccination and again five weeks after vaccination to confirm vaccination status.  A 
male goat was introduced to each group at four weeks post-vaccination to impregnate the 
ewes.  At 110 days of gestation, determined as described above, challenged with wild-
type 16M.  Depending upon the protection induced, goats either aborted or gave birth to 
kids.  Kids that were found dead were not necessarily considered aborted, since 
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TABLE 13.  Histologic changes of pregnant goats infected with BM?asp24 
Dam # 
Changes in 
Spleen Changes in Liver 
Changes in 
Parotid Lymph 
Node 
Changes in 
Supramammary 
Lymph Node 
Changes in 
Mammary Gland 
#8 0 congestion 
2 activity in 
nodules 
0 sinusoidal 
hyperplasia 
2 hemorrhage 
PLN 
0 congestion 
0 inflammation 
1 B cell 
expansion  
1 T cell 
expansion 
1 histiocytosis 
1 B cell 
expansion 
0 T cell 
expansion 
1 sinusoidal 
histiocytosis 
mild lactation 
#12 4 congestion 
3 activity in 
nodules 
0 sinusoidal 
hyperplasia 
4 hemorrhage 
PLN 
0 congestion 
0 inflammation 
0 B cell 
expansion  
0 T cell 
expansion 
0 histiocytosis 
4 B cell 
expansion 
1 T cell 
expansion 
0 sinusoidal 
histiocytosis 
Lactating 
2+ mononuclear 
inflammation in 
interstitium 
#15 0 congestion 
1 activity in 
nodules 
0 sinusoidal 
hyperplasia 
0 hemorrhage 
PLN 
1 congestion 
0 inflammation 
N/A 4 B cell 
expansion 
2 T cell 
expansion  
2= sinusoidal 
histiocytosis 
lactating 
4+ mononuclear 
inflammation 
PMN 
(interstitial); 
early 
microgranuloma 
#35 1 congestion 
2 degree of 
activity in 
nodules 
1 sinusoidal 
hyperplasia 
2 hemorrhage 
PLN 
0 congestion 
1+ mononuclear 
inflammation 
(portal area) 
3 B cell 
expansion 
1 T cell 
expansion  
1 histiocytosis 
4 B cell 
expansion 
3 T cell 
expansion 
1 sinusoidal 
histiocytosis 
Mild lactation 
#45 0 congestion  
3 activity in 
nodules 
1 sinusoidal 
hyperplasia 
1 hemorrhage 
PLN 
1 congestion 
0 inflammation 
0 B cell 
expansion  
0 T cell 
expansion 
0 histiocytosis 
4 B cell 
expansion 
2 T cell 
expansion 
1 sinusoidal 
histiocytosis 
Active lactation  
3 mononuclear 
infiltrate; early 
microgranuloma 
 
#47 0 congestion 
1 degree of 
activity in 
nodules 
1 sinusoidal 
hyperplasia 
0 hemorrhage 
PLN 
0 congestion 
2+ mononuclear 
inflammation 
(portal area) 
4 B cell 
expansion  
1 T cell 
expansion  
1 histiocytosis 
4+ B cell 
expansion 
3+ T cell 
expansion 
1 sinusoidal 
histiocytosis, 
slight 
hemorrhage 
4 inflammation 
mononuclear with 
large, well-formed 
microgranulomas, 
plasma cytosis, 
PMNs at 2 
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TABLE 14.  Histologic changes of goat fetuses infected with BM?asp24 
Kid or fetus # Changes in Spleen Changes in Lung Changes in Liver 
#8A 2 congestion 
0 B cell expansion 
2 T cell expansion 
0 sinusoidal hyperplasia 
1 atelactasis 
2 congestion 
1 hemorrhage 
2 inflammation (99% 
mononuclear) 
0 congestion 
1 sinusoidal 
inflammation 
2 portal mononuclear 
inflammation 
#8B 1 congestion 
1 B cell expansion 
1 T cell expansion 
0 sinusoidal hyperplasia 
5 atelactasis 
1 congestion 
2 hemorrhage 
1 inflammation (99% 
mononuclear) 
5 congestion 
0 inflammation 
#12A 2-3 congestion 
3-4 B cell expansion 
1-2 T cell expansion 
0 sinusoidal hyperplasia 
4 atelactasis 
3 congestion 
0 hemorrhage 
0 inflammation 
0 congestion 
1 portal mononuclear 
aggregation 
#15A no score putrefied 4 atelactasis 
0 congestion 
0 hemorrhage 
2 serous inflammation 
putrefied-can’t assess 
 
 
#35A 2 congestion 
3 B cell expansion 
1 T cell expansion 
0 sinusoidal hyperplasia 
1 atelactasis (alveolar 
rupture marked) 
0 congestion 
1 hemorrhage 
0 inflammation 
0 congestion 
0 inflammation 
#35B 1 congestion 
2 B cell expansion 
3 T cell expansion 
1 sinusoidal hyperplasia 
1 atelactasis (alveolar 
rupture marked) 
0 congestion 
1 hemorrhage 
0 inflammation 
0  congestion 
0 inflammation 
#45A 3-4 congestion 
3 B cell expansion 
1 T cell expansion 
0 sinusoidal hyperplasia 
0  atelactasis 
0 congestion 
0 hemorrhage 
0 inflammation 
1 congestion, marked 
hematopoeisis 
0 inflammation 
#47A 1 congestion 
3 B cell expansion 
3 T cell expansion 
0 sinusoidal hyperplasia 
3 atelactasis 
2 congestion 
1 hemorrhage 
2 inflammation (90% 
mononuclear, 10% 
PMN) 
2 congestion 
0 inflammation 
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TABLE 15.  Histologic changes of pregnant goats infected with BM?virB2 
Dam # 
Changes in 
Spleen Changes in Liver 
Changes in 
Parotid Lymph 
Node 
Changes in 
Supramammary 
Lymph Node 
Changes in 
Mammary Gland 
#4 0 congestion 
0-1 activity in 
nodules 
0 sinusoidal 
hyperplasia 
3 hemorrhage 
PLN 
0  hemorrhage 
0 inflammation 
1 B cell 
expansion 
0 T cell 
expansion 
0 histiocytosis 
1+ focal B cell 
expansion 
0 T cell 
expansion 
1 sinusoidal 
histiocytosis 
Lactating 
 
1+ inflammation 
#5 0 congestion  
3 activity in 
nodules 
1 sinusoidal 
hyperplasia 
2 hemorrhage 
PLN 
0 hemorrhage 
0 inflammation 
0 B cell 
expansion 
0 T cell 
expansion 
0 histiocytosis 
1 B cell 
expansion 
2 T cell 
expansion 
1 sinusoidal 
histiocytosis 
Lactating 
2+ lymphocytic 
infiltrate of 
granuloma 
with mature 
macrophages 
#7 0 congestion  
4 activity in 
nodules 
0 sinusoidal 
hyperplasia 
4 hemorrhage 
PLN 
0 hemorrhage 
1+ mononuclear 
inflammation 
(portal area) 
1 B cell 
expansion 
1 T cell 
expansion 
1 histiocytosis 
2 B cell 
expansion 
2 T cell 
expansion 
1 sinusoidal 
histiocytosis 
Lactating 
1+ mononuclear 
inflammation 
(interstitial) 
#13 1 congestion 
4 degree of 
activity in 
nodules 
2 sinusoidal 
hyperplasia 
1 hemorrhage 
PLN 
0 hemorrhage 
1 mononuclear 
inflammation 
(portal area) 
0 B cell 
expansion 
0 T cell 
expansion 
0 histiocytosis 
1 B cell 
expansion 
3 T cell 
expansion 
2 sinusoidal 
histiocytosis 
(neutrophils at   
3)   
N/A 
#23 1 congestion  
2 activity in 
nodules 
2 sinusoidal 
hyperplasia  
1 hemorrhage 
PLN 
1 hemorrhage 
0 inflammation 
0 B cell 
expansion 
0 T cell 
expansion 
0 histiocytosis 
2 B cell 
expansion 
0 T cell 
expansion 
0 sinusoidal 
histiocytosis 
 
Lactating 
 
0    inflammation  
#44 1 congestion 
1 degree of 
activity in 
nodules 
(lymphoid 
depletion) 
0 sinusoidal 
hyperplasia 
3 hemorrhage 
with 
neutrophilic 
PMNs 
0 hemorrhage 
1+ mononuclear 
inflammation 
(portal area) 
4 B cell 
expansion 
1 T cell 
expansion 
0 histiocytosis 
N/A mild lactation 
2 focal 
mononuclear 
inflammation 
with early 
granuloma 
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TABLE 16.  Histologic changes of goat fetuses infected with BM?virB2 
Kid or fetus # Changes in Spleen Changes in Lung Changes in Liver 
#4A 1 B cell expansion 
2 T cell expansion 
2 degree of atelactasis 
4 congestion 
2 hemorrhage 
3 inflammation (60% 
mononuclear, 40% 
PMN 
0 congestion 
0.5-1 sinusoidal 
mononuclear 
aggregation 
#5A 2 B cell expansion 
2 T cell expansion 
1 atelactasis 
1 congestion 
1 hemorrhage 
1 inflammation (90% 
mononuclear, 10% 
PMN) 
0 congestion 
0 inflammation 
#5B 2 B cell expansion 
2 T cell expansion 
2 atelactasis 
3 congestion 
4 hemorrhage 
2 inflammation (focal-
50% mononuclear, 
50% PMN) 
1 congestion 
0.5 inflammation 
(sinusoidal 
mononuclear 
aggregates) 
#7A 1 congestion 
2 B cell expansion 
1 T cell expansion 
1 atelactasis 
1 congestion w/ 
emphysema 
0 congestion 
0 inflammation 
#7B 1 congestion 
3 B cell expansion 
4 atelactasis 
2 congestion 
2 hemorrhage 
2 inflammation (90% 
mononuclear, 10% 
PMN) 
0 congestion 
0 inflammation 
#13A 1 congestion 
3 B cell expansion 
2 T cell expansion 
4 atelactasis 
4 congestion 
1 hemorrhage 
4 inflammation (50-50). 
5 congestion 
0 inflammation 
#23A 3 B cell expansion 
2 T cell expansion 
4 atelactasis 
3 congestion 
1 hemorrhage; (mild 
accumulation 
mononuclear cells) 
0 congestion 
0 inflammation 
#23B 1 congestion 
4 B cell expansion 
1 T cell expansion 
4 atelactasis 
3 congestion 
3 hemorrhage 
2 inflammation (90% 
mononuclear, 10% 
PMN). 
0 congestion 
0 inflammation 
#44A N/A 1 atelactasis; agonal 
emphysema 
3 congestion 
0.5 inflammation 
#44B 0-1 congestion 
1 B cell expansion 
4 sinusoidal hyperplasia 
N/A 0 congestion 
0.5 inflammation 
(mononuclear-
sinusoidal) 
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this requires additional criteria such as culture status and approximate age of the kid to 
determine whether it was aborted because of challenge or died due to environmental 
factors (Table 17).  Goats that were not vaccinated but challenged with 16M had the 
greatest numbers of kids that had suspect birth statuses: aborted, weak, or dead.  All kids 
in the Rev 1 vaccine group displayed normal birth status.  Goats vaccinated with 
BM?asp24 had a few suspect births upon original designation.  Upon closer inspection, 
however, goat # 15 aborted 16 days before it was challenged, which may have been due 
to environmental conditions.  Goat #44 aborted only 12 days after it was challenged, 
which may be considered an abortion, however Brucella recovery from the tissues would 
need to be considered to confirm this point.  For goats vaccinated with BM?virB2, 
several goats had suspect birth statuses, however two of these, #20 and #22, aborted 
before the date of challenge.  Goat #39 aborted twins 22 days after challenge, and this 
may represent a lack of protection against abortion. 
At one set timepoint, after all the goats had kidded, all dams were all bled then 
necropsied en masse.  Card tests were performed on serum samples to determine the 
presence of Brucella-specific antibodies (Tables 18 and 19).  Tissues were cultured for 
the presence of the challenge bacteria.  Isolated colonies were tested to ensure it was 
Brucella, and PCR verified to determine whether it was vaccine strain or wild-type 
organism.  In the unvaccinated/16M challenge group, the majority of the goats (7/9) and 
kid pairs (9/16) were culture positive from the challenge, which was an expected result 
(Table 20).  Goats vaccinated with Rev 1 were highly protected against virulent 
challenge, which was also expected from this experiment.  Only one goat out of seven 
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TABLE 17.  Birth status of goats from efficacy study 
Unvaccinated   BM?asp24  
#5 1 live, 1 dead  #9 1 live 
#26 2 dead on arrival  #10 1 live 
#36 aborted  #11 1 live 
#40 1 live  #12 2 live 
#46 1 live (weak)  #13 1 live 
#48 2 live (weak)  #14 2 live 
#144 3 in utero  #15 aborted 
#164 2 dead on arrival  #44 2 aborted 
#172 2 live    
     
     
Rev 1   BM?virB2  
#2 2 live  #16 2 live 
#4 1 live  #17 2 live 
#6 1 live  #18 2 live 
#8 1 live  #20 aborted 
#27 1 live  #22 aborted 
#47 2 live  #33 1 live 
#49 2 live  #39 2 aborted 
   #42 mummy 
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TABLE 18: Card tests results from efficacy study controls 
    
 
Saline 
5 weeks  
post-vaccination 
 
Pre-challenge  
(18 weeks post-vaccination) 
Necropsy  
(7 weeks post-challenge) 
#5 - - + 
#26 - - + 
#36 - - ns 
#40 - - + 
#46 - - ns 
#48 - - + 
#144 n/a - ns 
#164 n/a - + 
#172 n/a - + 
 
 
 
Rev1 
5 weeks  
post-vaccination 
Pre-challenge 
 (18 weeks post-vaccination) 
Necropsy  
(7 weeks post-challenge) 
#2 - - - 
#4 - - - 
#6 - - - 
#8 +/- - - 
#27 - - - 
#47 + - + 
#49 - - + 
 
 123 
 
 
 
TABLE 19: Card test results for efficacy study vaccine strains 
BM?virB2 
5 weeks 
 post-vaccination 
Pre-challenge 
 (18 weeks post-vaccination) 
Necropsy  
(7 weeks post-challenge) 
#16 + + + 
#17 + - + 
#18 + + + 
#20 + - + 
#22 + + + 
#33 + - - 
#39 + - ns 
#42 + + + 
 
 
    
BM?asp24 
5 weeks 
 post-vaccination 
Pre-challenge  
(18 weeks post-vaccination) 
Necropsy 
 (7 weeks post-challenge) 
#9 + - + 
#10 + + + 
#11 + + + 
#12 + + + 
#13 + + + 
#14 + + + 
#15 + + + 
#44 + + + 
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TABLE 20.  Recovery of Brucella from goat tissues: unvaccinated control group 
Dams      Kids   
  
 
 
PLN Liver Spleen SMLN MG   
Abomasal 
fluid lung 
#5 58 0 0 0 2 #5-A/B >1000 
>1000, 
500 
#26 5 0 5 300 Lawn #26-A/B 0 0,3 
#36 7 0 0 0 0 #36-A 0 0 
#40 0 0 0 0 0 #40-A 0 200 
#46 8 1 20 0 0 #46-A 0 0 
#48 0   7 3 12 #48-A/B >1000 Lawn, 13 
#144 0 0 0 0 1 #144A/B/C 0 0 
#164 0 3 3 55 >1000 #164-A/B lawn 300, 33 
#172 0 0 0 0 0 #172-A/B 0 0 
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was culture positive and 0/10 of the kids were positive, which is a very high vaccine 
efficacy (Table 21).  Goats vaccinated with BM?asp24 were generally well protected 
against challenge, though not to the same degree as Rev1 vaccinates (Table 22).  Of the 
dams, 3/8 had recovered Brucella from tissues, and only 1/11 kids were positive.  
Interestingly, dam #14, which was highly culture positive, retained the vaccine strain in 
the tissues as revealed by PCR (Fig.  43).  The kids, however, were positive for the 
challenge organism in the sample of colonies used as template.  These results are 
consistent with results from the safety study, in which the BM?asp24 mutant did not 
colonize the fetal tissues.  The absence of challenge organism in the dam was likely due 
to the limited sampling of bacteria for PCR.  It is possible that the primary population 
isolated was the vaccine strain, but that challenge organism persisted in the dam as well.  
In this goat, the vaccine strain was able to persist for an extended period.  Goats #11 and 
#44, which had very low numbers of recoverable bacteria, were positive only for the 
challenge strain.  Overall, the vaccine was very protective against challenge infection.  
The use of elevated vaccine dose of 1x109 may have contributed to this persistence and 
maternal pathology.  A reduced dose of BM?asp24 may be necessary, similar to Rev 1 
that was utilized at a 1x106 dose.   
The majority of goats vaccinated with BM?virB2 were protected against 
challenge infection, though not as highly as Rev 1 (Table 23).  For the dams, 3/8 were 
culture positive for the challenge organism, and only 1/12 of the kids were culture 
positive.  Goat #22 portrayed the highest tissue colonization levels, and this goat 
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TABLE 21.  Recovery of Brucella from goat tissues: Rev 1 vaccine group 
Dams      Kids   
 PLN Liver Spleen SMLN MG  
Abomasal 
Fluid Lung 
#2 0 0 0 0 0 #2-A/B 0 0 
#4 0 0 0 0 0 #4-A 0 0 
#6 0 1 2 0 0 #6-A 0 0 
#8 0 0 0 0 0 #8-A 0 0 
#27 0 0 0 0 0 #27-A 0 0 
#47 0 0 0 0 0 #47-A/B 0 0 
#49 0 0 0 0 0 #49-A/B 0 0 
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TABLE 22.  Recovery of Brucella from goat tissues: BM?asp24 vaccine group 
Dams      Kids   
  PLN Liver Spleen SMLN MG   
Abomasal 
Fluid Lung 
#9 0 0 0 0 0 #9-A 0 0 
#10 0 0 0 0 0 #10-A 0 0 
#11 0 1 1 1 1 #11-A 0 0 
#12 0 0 0 0 0 #12A/B 0 0 
#13 0 0 0 0 0 #13-A 0 0 
#14 0 1 0 >1000 Lawn #14A/B lawn 1, 54 
#15 0 0 0 0 0 #15-A 0 n/a  
#44 1 2 3 1 1 #44A/B 0 0 
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FIG.  43 .  PCR validation of maternal and fetal isolates.  Isolates recovered from goats 
vaccinated with BM?asp24 and challenged with 16M were heat killed and used for PCR 
using primers flanking the deletion region.  Products of knockout strains are smaller by 
approximately 530 bp.  Lane 1, Hyperladder I; lane 2, dam #11 liver isolate; lane 3, 
negative PCR control; lanes 4-5 dam #14 SMLN; lane 6, #14 mammary gland; lane 7, 
#14 liver; lane 8, kid #14-A lung; lane 9, kid #14-B lung; lanes 10-17 dam #44 various 
tissues including PLN, SMLN, liver, and MG; lane 18, genomic DNA from wild-type 
16M; lane 19, genomic DNA from BM?asp24. 
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TABLE 23.  Recovery of Brucella from goat tissues: BM?virB2 vaccine group 
Dams      Kids   
 PLN Liver Spleen SMLN MG  
Abomasal 
Fluid Lung 
#16 0 0 0 0 0 #16-A/B 0 0 
#17 0 0 0 0 0 #17-A/B 0 0 
#18 0 0 0 >1000 0 #18-A/B 200 0 
#20 2 0 0 0 0 #20-A 0  
#22 27 500 400 >1000 Lawn #22-A 0 0 
#33 0 4 1 0 0 #33-A 0 0 
#39 0 0 0 0 0 #39-A/B 0 0 
#42 0 0 0 0 0 #42-A 0 0 
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aborted the day of challenge.  Since there was not recovered Brucella from the fetus, it is 
possible that this goat aborted for another reason, and perhaps was more susceptible to 
the challenge infection due to the abortion and stressed condition.  Overall, the 
BM?virB2 mutant is a good vaccine candidate for the majority of goats, though not as 
significant as Rev 1, but is a safer candidate than the Rev 1 vaccine strain. 
 
Immune responses of goats from the efficacy study.  Evaluation of the 
humoral immune response was performed in order to determine whether IgG levels 
could be used as a marker for protection.  As expected, the unvaccinated control group 
remained seronegative until after challenge (Fig.  44).  Rev 1 vaccinates showed 
increased IgG levels after vaccination, which decreased over time and did not increased 
slightly after challenge (Fig.  45).  Goats vaccinated with BM?asp24 had increased 
levels of IgG at all timepoints after the vaccination, though higher IgG titers were seen 
after vaccination than after challenge (Fig.  46).  The goat with the highest IgG levels 
after challenge was dam #14.  This goat retained a great deal of the vaccine strain, which 
could explain the titer.  Similarly, BM?virB2 vaccinates showed increased IgG levels at 
all timepoints post-vaccination (Fig.  47).  Dams #18 and #22 retained high numbers of 
challenge organism in tissues, which correlates with their high IgG levels. 
.
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FIG.  44.  Goat efficacy study: IgG titers of unvaccinated goats challenged with 16M.  
Goats were mock vaccinated with PBS before pregnancy, then challenged with 1x107 
CFU wild-type B. melitensis 16M conjunctivally during the third trimester of pregnancy.  
Goats were bled the day of vaccination, 5 weeks post-vaccination, the day of challenge 
(18 weeks post-vaccination), and at necropsy (7 weeks post-challenge).  Serum samples 
were assayed via ELISA to detect IgG antibodies due to the vaccination.  Baseline titers 
were set at 5 as described in the text.  Titers for samples were based upon the first 
dilution in the series that the OD reading was below the cut-off OD value.  The IgG 
levels are therefore represented by the two fold increase in IgG levels over the duration 
of infection. 
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FIG.  45.  Goat efficacy study: IgG titers of goats vaccinated with Rev 1 and challenged 
with 16M.  Goats were vaccinated with Rev 1 at 1x106 CFU (I.M.) before pregnancy, 
then challenged with 1x107 CFU wild-type B. melitensis 16M conjunctivally during the 
third trimester of pregnancy.  Goats were bled the day of vaccination, 5 weeks post-
vaccination, the day of challenge (18 weeks post-vaccination), and at necropsy (7 weeks 
post-challenge).  Serum samples were assayed via ELISA to detect IgG antibodies due to 
the vaccination.  Baseline titers were set at 5 as described in the text.  Titers for samples 
were based upon the first dilution in the series that the OD reading was below the cut-off 
OD value.  The IgG levels are therefore represented by the two fold increase in IgG 
levels over the duration of infection. 
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FIG.  46.  Goat efficacy study: IgG titers of goats vaccinated with BM?asp24 and 
challenged with 16M.  Goats were vaccinated with1x109 CFU BM?asp24 
(subcutaneous) before pregnancy, then challenged with 1x107 CFU wild-type B. 
melitensis 16M conjunctivally during the third trimester of pregnancy.  Goats were bled 
the day of vaccination, 5 weeks post-vaccination, the day of challenge (18 weeks post-
vaccination), and at necropsy (7 weeks post-challenge).  Serum samples were assayed 
via ELISA to detect IgG antibodies due to the vaccination.  Baseline titers were set at 5 
as described in the text.  Titers for samples were based upon the first dilution in the 
series that the OD reading was below the cut-off OD value.  The IgG levels are therefore 
represented by the two fold increase in IgG levels over the duration of infection. 
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FIG.  47.  Goat efficacy study: IgG titers of goats vaccinated with BM?virB2 and 
challenged with 16M.  Goats were vaccinated with1x109 CFU BM?virB2 
(subcutaneous) before pregnancy, then challenged with 1x107 CFU wild-type B. 
melitensis 16M conjunctivally during the third trimester of pregnancy.  Goats were bled 
the day of vaccination, 5 weeks post-vaccination, the day of challenge (18 weeks post-
vaccination), and at necropsy (7 weeks post-challenge).  Serum samples were assayed 
via ELISA to detect IgG antibodies due to the vaccination.  Baseline titers were set at 5 
as described in the text.  Titers for samples were based upon the first dilution in the 
series that the OD reading was below the cut-off OD value.  The IgG levels are therefore 
represented by the two fold increase in IgG levels over the duration of infection. 
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DISCUSSION 
Since Brucella vaccine strains approved for use in livestock may elicit negative 
side effects upon administration or even in the long-term such as chronic shedding and 
repeated abortions, improved strains were considered for use in target species.  The 
mouse model is adequate for evaluating attenuation and protection against infection, but 
the model’s major downfall is the lack of practical information generated for target 
species.  Specifically, protection against abortion can not be predicted, which is a major 
component of vaccine development for Brucella.  The goat, a target species, was 
therefore used to model the effects of novel unmarked deletion strains on fetal survival 
and protection.  The goat was chosen due to its reduced size, reproducible experimental 
abortions and infections, and for hosting Brucella melitensis infections naturally (21).  
Vaccine candidates in this study were selected based upon their attenuation and 
protective ability demonstrated in the mouse model.  The selected vaccine candidates 
were evaluated in pregnant ruminants to ensure the strains were safe (i.e. do not cause 
abortion when administered to pregnant animals) and that they would afford protection 
against abortion and infection upon subsequent exposure to virulent Brucella.  For the 
first set of criteria, two vaccine strains, BM?asp24 and BM?virB2, were safe in 
pregnant goats administered during mid-gestation.  The BM?virB2 mutant was not 
cultured from either dams or kids, suggesting that this strain is cleared quickly from the 
host at the reduced dose and 1x107 CFU would therefore be a safe strain at that dose for 
use in pregnant goats.  BM?asp24 was isolated from most of the maternal tissues, 
suggesting a reduced rate of clearance of this strain.  However, BM?asp24 was not 
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cultured from any of the kids despite the maternal colonization.  On the basis of safety of 
these candidate vaccine strains, BM?asp24 and BM?virB2 were considered to be 
improvements over the currently utilized vaccine strain Rev 1 which can cause abortion 
when given to goats during the late stages of gestation (19).  
Vaccine strains may need to persist in the host for a period sufficient to evoke 
protective immunity.  As such, the vaccine strain should ideally persist in the lymph 
nodes to invoke the host’s immune response, but not be reactivated at sexual maturity or 
during pregnancy, to eliminate the possibility of abortions (12).  Since the BM?asp24 
vaccine strain is able to persist and is not pathogenic to the fetus, it may be the best 
novel vaccine candidate tested.  The BM?virB2 mutant was safe in pregnant goats and 
protected the majority of the dams against subsequent infection without persistence in 
maternal tissues.  The increased safety of this BM?virB2 indicates a benefit over other 
strains, such as Rev 1.  
Histological changes were assessed to identify pathology associated with the 
vaccination.  BM?asp24 generally had more changes associated with an inflammatory 
response and activity in the lymph nodes than BM?virB2.  This was expected since the 
latter did not appear to persist in the host for as long.  These changes were not as severe 
as goats vaccinated with either BM?cydBA or 16M, paralleling the attenuated phenotype 
seen in the mouse model. 
The two safe vaccine candidates were then used in efficacy trials to decide 
whether they would provide increased levels of protection against challenge, the second 
important criterion.  The majority of BM?virB2 vaccinated goats were protected against 
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challenge as evidenced by lack of isolation of challenge organism from tissues, but the 
goats that were culture positive had very high numbers of challenge organism recovered.  
Increasing the dose for the BM?virB2 vaccine may afford better protection to the 
majority of goats.  Since the vaccine cleared rapidly from goats in the safety study at two 
logs lower of a dose, increasing the dose a log may still be safe, but would need to be 
considered in the event a pregnant animal received this higher vaccine dose.  When 
cattle are given RB51 at 1x109 while pregnant, they do not often suffer abortions or 
placentitis.  When they are given the typical RB51 vaccine dose of 1-3.4 X 1010 
organisms, however, they may suffer from placental or fetal infections (69).  For this 
reason, even safe candidates can become pathogenic to the pregnant host at a high 
enough dose, and this factor will need to be assessed. 
BM?asp24 vaccinated goats displayed a result differing from BM?virB2.  In the 
majority of animals vaccinated with BM?asp24, no or very low numbers of challenge 
organism were recovered from either the dams or kids.  There was one dam in the 
BM?asp24 group with a very high recoverable load of vaccine strain.  For this strain, the 
dose may need to be lowered to decrease the maternal pathology and persistence of the 
organism.  Regardless of this persistence, vaccination with 1x109 still was safe for the 
fetuses, since vaccine strain was not isolated from the kids, another indication of altered 
tropism of the mutant.  
Rough strains have become a huge focus in the development of cattle vaccines 
due to the lack of problems with standard diagnostics.  These same rough strains have 
not showed superior protection in goats over current vaccine strains when administered 
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at high doses, however (20).  Rough mutants are typically safe in goats, depending upon 
the administration dose, but they do not elicit long-term protection and will not be 
adequate for use in the field (65).  It was hypothesized that goats need both cell-
mediated as well as humoral immunity to be protected against B. melitensis, which may 
explain the protective ability of Rev 1, a smooth organism (20).  It is possible that 
improved vaccine strains should not sacrifice the immunogenic effect of O-antigen, and 
instead improved diagnostics need to be considered if smooth vaccines continue to be 
used. 
Overall, two safe vaccine candidates, BM?asp24 and BM?virB2, were identified 
in the caprine model.  The vaccines afforded protection against abortion and fetal and 
maternal infection in efficacy trials.  The degree of pathology and infection to the dams 
from BM?asp24, though minor, may be lessened by decreasing the amount of vaccine 
strain administered from 1x109 to a dose closer to the Rev 1, which is given at 1x106.  
Both strains would need to be re-evaluated in bison, elk and cattle with B. abortus 
knockouts to ensure the protection afforded would be similar in other target species.  
Since there has not been an identified silver bullet vaccine, it is possible that one mutant 
vaccine candidate will not protect all target species.  The goat model has demonstrated 
some positive results that need to be considered further for vaccine development. 
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SUMMARY AND CONCLUSION 
 
B. abortus and B. melitensis are two zoonotic pathogens causing brucellosis, 
which is a human health threat and a disease of global economic importance.  Some 
animals that are infected will abort during mid to late gestation, spreading the disease to 
others in the herd and causing reproductive losses to producers.  The ability Brucella to 
persist in phagocytic cells is a central factor in the organism’s survival.  Recent 
knowledge of specific genes directly involved in the pathogenesis of the organism, such 
as O-antigen and the type IV secretion system, has allowed researchers to alter 
trafficking, and thus the fate of the bacteria in vitro and in the mouse model.  Removing 
genes that are important to the organism’s pathogenesis has led to the development of 
attenuated strains that do not cause typical disease in the host, and are possible novel live 
vaccine candidates for evaluation.   
Brucella species defective in the manBA, virB operon, cydBA and asp24 genes 
were previously identified in this lab as attenuated in macrophages and or mice, and 
were chosen as targets to create vaccine strains.  Two of these genes, manBA and virB2, 
are involved in known virulence mechanisms of the bacteria, LPS and the T4SS, 
respectively.  These genes were chosen not only to indicate their importance to 
virulence, but also to elucidate their role in protective ability of vaccine strains.  
Removal of the specific genes important for the organism’s survival without retained 
possession of antibiotic resistance led to novel strains sufficient to test in animals.  The 
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two species of Brucella chosen to host the deletions are both of economic importance for 
agricultural reasons and are both human pathogens.   
In the mouse model, ?manBA, ?virB2, and ?asp24 exhibited varied survival 
characteristics, ranging from rapidly cleared to more persistent though attenuated.  Due 
to the varied kinetics of clearance in mice, these mutants were considered good models 
to determine whether the duration of persistence of vaccine strains were directly 
correlated with protective ability.  In general, the Brucella mutant that persisted the 
longest, BM?asp24, protected mice to the highest degree against homologous and 
heterologous challenge infection.  BA?asp24 also protected mice to a very high degree 
against both types of challenge, though it did not persist as long as BM?asp24.  It is 
possible that in addition to the persistence, there is a correlation between protection and 
presence of known virulence factors.  In particular, the asp24 deletions possess both LPS 
as well as the T4SS.  It is possible that the great degree of protection is due, in part, to 
the presence of both factors.  Cytokine profiles need to be re-evaluated in another strain 
of mice and at different timepoints to correlate the CMI responses with the different 
strains. 
The goat model was necessary to assess use of BM?asp24, BM?cydBA, and 
BM?virB2 in target species that are naturally infected with Brucella.  The goat is used as 
a model to assess the degree of pathology associated with the vaccine strain itself, as 
well as protection against abortion and infection, all of which are the criteria for Brucella 
vaccine strains for use in livestock.  Both BM?asp24 and BM?virB2 were considered 
safe vaccine candidates in the pregnant goat model since they did not cause abortion or 
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colonize fetal tissues.  BM?asp24 was isolated from most of the maternal tissues in the 
goat safety studies, suggesting a slower rate of clearance of the vaccine strain than for 
BM?virB2, which was not isolated from any maternal or fetal tissues.  This observation 
mirrors the mouse experiments, where BM?asp24 is cleared from mice more slowly 
than BM?virB2.  Both strains were protective in the majority of goats against abortion 
and infection.  The BM?asp24 vaccine strain persisted in one goat, however, and so a 
lowered dose may need to be considered to decrease maternal pathology while retaining 
the protective ability.  The BM?virB2 did not protect the goats as well as Rev 1 or 
BM?asp24, and so a higher dose may need to be considered to increase the protection 
levels, though this may increase the persistence.  It is hoped that altering the dose will 
improve protection levels while maintaining the safety of the strains.  Alternatively, a 
delivery system such as microencapsulation may offer a solution for release of safe 
doses the vaccine for extended periods, thus enhancing protection. 
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APPENDIX 
 
 
Histology slides from the goat safety study 
 
 
 
 
 
 
 
 
A-1.  H&E stain of liver sample from fetal goat #28-A, 16M vaccinated group at 20X 
magnification.  The tissue exhibits mild sinusoidal and marked portal triad mononuclear 
inflammation. 
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A-2.   H&E stain of liver sample from fetal goat #48-b from 16M vaccinated group at 
40X magnification.  The tissue sample shows early sinusoidal microgranuloma 
formation. 
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A-3.  H&E stain of spleen from goat #29 of the 16M vaccinated group at 10X 
magnification.  The tissue shows excessive amounts of polymorphonuclear cells and 
mild hemorrhage. 
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A-4.  H&E stain of spleen from fetal goat #48-A of the 16M vaccinated group at 4X 
magnification.  The tissue shows marked B and T cell zone expansion with mild 
congestion. 
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A-5.  H&E stain of fetal goat #43-B from the BM?cydBA vaccine group at 40X 
magnification.  The tissue shows a marked sinusoidal microgranuloma around the 
terminal hepatic venule. 
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A-6.  H&E stain of spleen from goat #32 of the BM?cydBA vaccinated group at 10X 
magnification.  The tissue shows excessive amounts of polymorphonuclear cells and 
mild hemorrhage. 
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A-7.   H&E stain of spleen from fetal goat #43-A of the BM?cydBA vaccinated group at 
4X magnification.  The tissue shows marked B and T cell zone expansion, moderate to 
high congestion, and mild sinusoidal hyperplasia. 
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A-8.  H&E stain of mammary gland from goat # 47 of the BM?asp24 vaccine group at 
10X magnification.  The tissue shows large, well-formed microgranulomas with a very 
high proportion of mononuclear infiltrate as well as polymorphonuclear cells. 
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A-9.  H&E stain of supramammary lymph node of goat #12 from BM?asp24 vaccinates 
at 4X magnification.  The tissue shows very active B cell expansion.  
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A-10.  H&E stain of spleen from goat # 44 from the BM?virB2 vaccinates at 4X 
magnification.  The tissue shows a marked lymphoid depletion and a moderate to high 
degree of hemorrhage. 
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